Village Farms International (VFF) 40-F/A 11 Apr 19 2018 FY Annual report (Canada) (amended) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2018shares
Document and entity information [abstract]
Document Type	40-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Trading Symbol	VFF
Entity Registrant Name	Village Farms International, Inc.
Entity Central Index Key	0001584549
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding	47,642,672

Consolidated Statements of Fina

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 11,920	$ 7,091
Trade receivables	11,292	11,259
Amounts due from joint venture	10,873	411
Other receivables	332	1,571
Inventories (note 5)	22,485	17,309
Prepaid expenses and deposits	889	810
Biological asset (note 6)	4,230	4,405
Total current assets	62,021	42,856
Non-current assets
Property, plant and equipment (note 7)	77,479	81,754
Investment in joint venture (note 8)	18,108	15,727
Other assets (note 9)	2,207	2,004
Total assets	159,815	142,341
Current liabilities
Line of credit	2,000
Trade payables	14,601	12,952
Current maturities of long-term debt (note 10)	3,414	2,620
Accrued liabilities	3,509	3,793
Current maturities of capital lease obligations	78	72
Total current liabilities	23,602	19,437
Non-current liabilities
Long-term debt (note 10)	32,445	35,760
Deferred tax liability (note 16)	1,920	4,825
Other liabilities	1,050	1,097
Capital lease obligations	102	179
Total liabilities	59,119	61,298
SHAREHOLDERS' EQUITY
Share capital (note 20)	60,872	36,115
Contributed surplus	2,198	1,726
Revaluation surplus (note 7)	4,321	4,321
Accumulated other comprehensive loss	(562)	(391)
Retained earnings	33,867	39,272
Total shareholders' equity	100,696	81,043
Total liabilities and shareholders' equity	$ 159,815	$ 142,341

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands	Total	Share capital [member]	Contributed surplus [member]	Revaluation surplus [member]	Accumulated other comprehensive (loss) income [member]	Retained earnings [member]	Common share [member]
Beginning balance at Dec. 31, 2016	$ 67,387	$ 24,954	$ 1,392	$ 6,132	$ (541)	$ 35,450
Beginning balance, shares at Dec. 31, 2016	38,882,945						38,882,945
Statement [LineItems]
Shares issued pursuant to public offering, net of issuance costs	$ 9,769	9,769
Shares issued pursuant to public offering, net of issuance costs, Shares							2,500,000
Shares issued on exercise of stock options, Value	59	59
Shares issued on exercise of stock options, Shares							91,667
Issuance of warrants for common shares	148		148
Share-based compensation, Value	1,519	1,333	186
Share-based compensation, Shares							768,000
Reclassification of previously recorded revaluation gain of land, net of tax	(1,811)			(1,811)
Net income	3,822					3,822
Ending balance at Dec. 31, 2017	$ 81,043	36,115	1,726	4,321	(391)	39,272
Ending balance, Shares at Dec. 31, 2017	42,242,612						42,242,612
Statement [LineItems]
Cumulative translation adjustment	$ 150				150
Shares issued pursuant to public offering, net of issuance costs	15,737	15,737
Shares issued pursuant to public offering, net of issuance costs, Shares							3,097,200
Shares issued pursuant to private placement of common shares, net of issuance costs	7,755	7,755
Shares issued pursuant to private placement of common shares, net of issuance costs, shares							1,886,793
Shares issued on exercise of stock options, Value	283	434	(151)
Shares issued on exercise of stock options, Shares							365,733
Share-based compensation, Value	1,454	831	623
Share-based compensation, Shares							50,334
Net income	(5,145)					(5,145)
Ending balance at Dec. 31, 2018	$ 100,696	$ 60,872	$ 2,198	$ 4,321	(562)	$ 33,867
Ending balance, Shares at Dec. 31, 2018	47,642,671						47,642,672
Statement [LineItems]
Cumulative translation adjustment	$ (171)				$ (171)

Consolidated Statements of (Los

Consolidated Statements of (Loss) Income and Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Profit or loss [abstract]
Sales	$ 150,000	$ 158,406
Cost of sales	(140,282)	(144,433)
Change in biological asset	(834)	265
Selling, general and administrative expenses	(15,562)	(15,413)
Income (loss) from operations	(6,678)	(1,175)
Interest expense,net	2,407	2,695
Foreign exchange loss (gain)	1,047	(26)
Other income	(131)	(46)
Share of (income) loss from joint venture	(2,381)	255
Gain on disposal of assets		(8,013)
(Loss) income before income taxes	(7,620)	3,960
(Recovery of) provision for income taxes	(2,475)	138
Net (loss) income	$ (5,145)	$ 3,822
Basic (loss) income per share	$ (0.11)	$ 0.10
Diluted (loss) income per share	$ (0.11)	$ 0.10
Other comprehensive (loss) income:
Foreign currency translation adjustment	$ (171)	$ 150
Gain on revaluation of land, net of tax		(1,811)
Comprehensive (loss) income	$ (5,316)	$ 2,161

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net (loss) income	$ (5,145)	$ 3,822
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization	7,027	7,586
Amortization of deferred charges		73
(Gain) loss on disposal of assets		(8,013)
Share of (income) loss from joint venture (note 8)	(2,381)	255
Interest expense	2,407	2,614
Share-based compensation	1,454	1,519
Deferred income taxes	(2,906)	109
Change in biological asset	834	(265)
Changes in non-cash working capital items (note 18)	(3,550)	(4,417)
Net cash (used in) provided by operating activities	(2,260)	3,283
Cash flows from investing activities:
Purchases of property, plant and equipment	(3,093)	(1,696)
Note receivable to joint venture (note 8)	(10,462)
Proceeds from sale of land	65
Net cash used in investing activities	(13,490)	(1,696)
Cash flows from financing activities:
Proceeds from borrowings	7,000	7,306
Repayments on borrowings	(7,706)	(14,320)
Interest paid on long-term debt	(2,417)	(2,614)
Proceeds from issuance of common stock, net	23,492	9,769
Proceeds from exercise of stock options	283	59
Payments on capital lease obligations	(71)	(59)
Net cash provided by financing activities	20,581	141
Effect of exchange rate changes on cash and cash equivalents	(2)	(10)
Increase in cash and cash equivalents	4,829	1,718
Cash and cash equivalents, beginning of year	7,091	5,373
Cash and cash equivalents, end of year	11,920	7,091
Supplemental cash flow information:
Income taxes paid (recovered)	$ 290	(25)
Supplemental disclosure of non-cash information:
Purchases of capital expenditures by financing capital lease		190
Issuance of warrants		$ 148

Nature of Operations

Nature of Operations	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Nature of Operations	1 NATURE OF OPERATIONS Village Farms International, Inc. (“VFF” the parent company, together with its subsidiaries, the “Company”) is incorporated under the Canada Business Corporation Act th The Company’s shares are listed on the Toronto Stock Exchange under the symbol VFF and are also listed in the United States on the Nasdaq Capital Market (“Nasdaq”) under the symbol VFF (note 24). The Company owns and operates sophisticated, highly intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells premium-quality tomatoes, bell peppers, and cucumbers. The Company also markets and sells third party produce through its subsidiaries. The Company, through its subsidiary VFCE, owns and operates a 7.0 MW power plant that generates electricity. In addition, the Company’s joint venture, Pure Sunfarms, is a licensed producer and supplier of cannabis products to be sold to other licensed providers and provincial governments across Canada and internationally.

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Basis of Presentation	2 BASIS OF PRESENTATION Basis of Presentation These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements were approved by the Board of Directors of the Company for issue on March 13, 2019. Management does not have the authority to amend the consolidated financial statements after the statements have been issued, without the approval by the Board of Directors of the Company. The preparation of consolidated financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company’s accounting policies. Basis of Measurement The consolidated annual financial statements have been prepared on the historical cost basis except for the following material items on the consolidated statements of financial position: • biological assets are measured at fair value less costs to sell; • land is valued at fair market value; and • marketable equity securities are measured at fair value through profit and loss. Functional and Presentation Currency The functional currency for each entity included in these consolidated financial statements is the currency of the primary economic environment in which the entity operates. These consolidated financial statements are presented in United States dollars (“U.S. dollars”) which have been rounded to the nearest thousands, except per share amounts. Currency conversion to U.S. dollars is performed in accordance with IAS 21, The Effects of Changes in Foreign Exchange Rates

Significant Accounting Policies

Significant Accounting Policies, Judgments and Estimation Uncertainty	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Significant Accounting Policies, Judgments and Estimation Uncertainty	3 SIGNIFICANT ACCOUNTING POLICIES, JUDGMENTS AND ESTIMATION UNCERTAINTY The significant accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements. Consolidation The consolidated financial statements of the Company consolidate the accounts of VFF and its subsidiaries. All intercompany transactions, balances and unrealized gains and losses from intercompany transactions are eliminated on consolidation. Joint Venture A joint venture is a contractual arrangement whereby the Company and other parties undertake an economic activity through a jointly controlled entity. Joint control exists when strategic, financial and operating policy decisions relating to the activities require the unanimous consent of the parties sharing control. Joint ventures are accounted for using the equity method and are recognized initially at cost. The Company recognizes its share of the post-acquisition income and expenses and equity movement in the venture. If the cumulative losses exceed the carrying amount of the equity investment, they are first applied to any additional advances that are receivable from the joint venture to the extent of the total amount receivable. Additional losses are recognized only to the extent that there exists a legal or constructive obligation. Segment Reporting Operating segments are reported in a manner consistent with internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer (“CEO”). Based on the aggregation criteria in IFRS 8, Operating Segments Foreign Currency Translation Monetary assets and liabilities denominated in foreign currencies are translated to the functional currency at the exchange rates in effect at the reporting date. Non-monetary Non-monetary Financial Instruments Financial assets and liabilities are recognized when the Company becomes party to the contractual provisions of the financial instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Financial liabilities are derecognized when the obligation specified in the contract is discharged, cancelled or expired. Financial assets and liabilities are offset and the net amount is reported on the consolidated statements of financial position when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously. Classification and Measurement The Company has assessed the classification and measurement of its financial assets and financial liabilities under IFRS 9 and has summarized the original measurement categories under IAS 39 and the new measurement categories under IFRS 9 in the following table: Measurement Category Original (IAS 39) New (IFRS 9) Financial Assets: Cash Trade receivables Marketable equity securities Other financial assets Amortized cost Amortized cost Available-for-sale Amortized cost Amortized cost Amortized cost Fair value through other comprehensive income Amortized cost Financial Liabilities: Trade payables Debt Derivative instruments Other financial liabilities Amortized cost Amortized cost Fair value through profit or loss Amortized cost Amortized cost Amortized cost Fair value through profit or loss Amortized cost There has been no change in the carrying value of our financial instruments or to previously reported figures as a result of changes to the measurement categories in the table noted above. Impairment of Financial Assets Prior to January 1, 2018, at each reporting date, the Company assessed whether there was objective evidence that a financial asset was impaired. The criteria used to determine if objective evidence of an impairment loss exists include: i) significant financial difficulty of the obligor; ii) delinquencies in interest or principal payments; and iii) it becomes probable that the borrower will enter bankruptcy or other financial reorganization. If such evidence existed, the Company recognized an impairment loss as follows: i) Financial assets carried at amortized cost: The loss equaled the difference between the amortized cost of the loan or receivable and the present value of the estimated future cash flows, discounted using the instrument’s original effective interest rate. The carrying amount of the asset was reduced by this amount either directly or indirectly through the use of an allowance account. ii) Available-for-sale Subsequent to January 1, 2018, the Company assesses all information available, including, on a forward-looking basis, the expected credit losses associated with its assets carried at amortized cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk. To assess whether there is a significant increase in credit risk, the Company compares the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date of initial recognition based on all information available, and reasonable and supportive forward-looking information. For trade receivables only, the Company applies the simplified approach as permitted by IFRS 9 which requires expected lifetime losses to be recognized from initial recognition of the receivables. Cash and Cash Equivalents Cash and cash equivalents consist of cash deposits held with banks, and other highly liquid short-term interest bearing securities with maturities at the date of purchase of three months or less. Trade Receivables Trade receivables are measured at amortized cost, net of allowance for expected credit losses. Credit is extended based on an evaluation of a customer’s financial condition. Accounts outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance by considering a number of factors, including the length of time accounts are past due, the Company’s previous loss history and the customer’s current ability to pay its obligation to the Company. Trade receivables are recorded net of lifetime expected credit losses. Inventories Inventories refer to deferred crop costs and other supplies and packaging which are incurred to date on current production and are not defined as a biological asset. Inventories of Company-grown produce consist of raw materials, labour and overhead costs incurred less costs charged to cost of sales throughout the various crop cycles, which end at various times throughout the year. Growing crops are accounted for in accordance with the Company’s policy on biological assets. Cost of sales is based on estimated costs over the crop cycle allocated to both actual and estimated future yields at each period-end The carrying value of agricultural produce is its fair value less costs to sell and complete at the date of harvest and is presented with biological asset on the consolidated statements of financial position. Supplies and packaging are recorded at the lower of cost or replacement cost. The cost of produce inventory purchased from third parties is valued at the lower of cost or net realizable value. Biological Asset Biological asset consists of the Company’s produce on the vines at year-end. Property, Plant and Equipment Recognition and measurement Property, plant and equipment are stated at cost less accumulated depreciation and impairment losses, except for land. Until the fiscal year ended December 31, 2016, land had been stated at cost, and is now stated at fair value and will be revalued every three years by an independent external appraiser. Any revaluation increase arising on appraisal of land is recognized in other comprehensive income on the consolidated statements of (loss) income and revaluation surplus on the statements of financial position. Any revaluation decrease arising on appraisal of land is also charged to other comprehensive income and, to the extent of any credit balance existing, debited to revaluation surplus in equity with the excess recognized in net income or loss, Property, plant and equipment costs include expenditures that are directly attributable to the acquisition of the asset. The cost of self-constructed assets includes the cost of materials and direct labour, any other costs directly attributable to bringing the assets to a working condition for their intended use, the costs of dismantling and removing the items and restoring the site on which they are located, and borrowing costs. When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. The gain or loss on disposal of an item of property, plant and equipment is determined by comparing the proceeds from disposal with the carrying amount of the property, plant and equipment, and is presented net within gain/loss on disposal of assets in the consolidated statements of (loss) income. Depreciation Depreciation is based on the cost of an asset less its residual value. Significant components of individual assets are assessed, and if a component has a useful life that is different from the remainder of that asset, that component is depreciated separately. Depreciation expense is recognized on a straight-line basis over the estimated useful lives of each component of an item of property, plant and equipment. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. Land is not depreciated. The estimated useful lives of the class of assets for the current and comparative periods are as follows: Classification Estimated Useful Lives Leasehold and land improvements 5-20 Greenhouses and other buildings 4-30 Greenhouse equipment 3-30 Machinery and equipment 3-12 Construction in process reflects the cost of assets under construction, which are not depreciated until placed into service. Impairment of Non-Financial Property, plant and equipment and intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable. For the purpose of testing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units or “CGUs”). An impairment loss is recognized for the amount, if any, by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell and value in use (being the present value of the expected future cash flows of the relevant asset or CGUs). Leased Assets Leases where the Company assumes substantially all the risks and rewards of ownership are classified as finance leases. Upon initial recognition, the leased asset is measured at an amount equal to the lower of its fair value and the present value of the minimum lease payments. Subsequent to initial recognition, the asset is accounted for in accordance with the accounting policy applicable to that asset. Other leases are operating leases and rent expenses are recognized in the Company’s consolidated statements of (loss) income. Borrowing Costs Borrowing costs attributable to the acquisition, construction or production of qualifying assets are added to the cost of those assets, until such time as the assets are substantially ready for their intended use. All other borrowing costs are recognized initially at fair value. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the consolidated statements of (loss) income over the year of the borrowings using the effective interest method. Revenue Recognition Prior to January 1, 2018, revenue from the sale of produce in the course of ordinary activities was measured at the fair value of the consideration received or receivable, net of returns, trade discounts and volume rebates. Revenue from the production and sale of power was measured at the fair value of the consideration received or receivable. Revenue was recognized when persuasive evidence existed that the significant risks and rewards of ownership have been transferred to the customer, recovery of the consideration was probable, the associated costs and possible return of goods could be estimated reliably, there was no continuing management involvement with the goods, and the amount of revenue could be measured reliably. If it was probable that discounts would be granted and the amount could be measured reliably, then the discount was recognized as a reduction of revenue as the sales were recognized. The timing of the transfer of risks and rewards occurred at the time the produce had been successfully delivered, the risk of loss had passed to the customer, and collectability was reasonably assured. The Company adopted IFRS 15, Revenue from Contracts with Customers Income Taxes The tax expense for the year comprises current and deferred tax. Tax is recognized in the consolidated statements of (loss) income, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the consolidated statements of financial position dates in the relevant tax jurisdiction. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of the amounts expected to be paid to the tax authorities. Deferred income tax is recognized, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively enacted at the consolidated statements of financial position dates and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred income tax assets are recognized only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Offsetting of deferred income tax assets and liabilities occurs only when the deferred income tax assets and liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities where there is an intention to settle the balances on a net basis. Share-Based Compensation The Company grants stock options and performance-based restricted share units (“RSUs”) to certain employees and directors. Stock options generally vest over three years (33% per year following the grant date) and expire after ten years. Each tranche in an award is considered a separate award with its own vesting period. The fair value of each tranche is measured at the date of grant using the Black-Scholes option pricing model. Compensation expense is recognized over the tranche’s vesting period by increasing contributed surplus based on the number of awards expected to vest. The number of awards expected to vest is reviewed at least annually, with any impact recognized immediately. The RSUs granted are expected to be settled using the Company’s own equity and issued from treasury. The equity-settled share-based compensation is measured at the fair value of the Company’s common shares as at the grant date in accordance with the terms of the RSU Plan. The fair value determined at the grant date is charged to income when performance based vesting conditions are met, based on the estimate of the number of RSUs that will eventually vest and be converted to common shares, with a corresponding increase in equity. Provisions Provisions, where applicable, are recognized in accrued liabilities when the Company has a present legal or constructive obligation as a result of past events, it is more likely than not that an outflow of resources will be required to settle the obligation, and the amount can be reliably estimated. Provisions are measured at management’s best estimate of the expenditure required to settle the obligation at the end of the reporting period, and are discounted to present value where the effect is material. (Loss) Income Per Share Basic income per share are computed using the weighted average number of common shares outstanding during the period. The treasury stock method is used for the calculation of diluted income per share. Under this method, the weighted average number of common shares outstanding assumes that the proceeds to be received on the exercise of dilutive share options are applied to repurchase common shares at the average market price for the period. Share options are dilutive when the average market price of the common shares during the period exceeds the exercise price of the options. Significant Accounting Judgments and Estimation Uncertainties The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income, and expenses. These estimates and judgments have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities in future periods. Critical accounting estimates and judgments i) Estimated useful lives of property, plant and equipment Management estimates the useful lives of property, plant and equipment based on the period during which the assets are expected to be available for use. The amounts and timing of recorded expenses for depreciation of property, plant and equipment for any period are affected by these estimated useful lives. The estimates are reviewed at least annually and are updated if expectations change as a result of physical wear and tear, technical or commercial obsolescence and legal or other limits to use. It is possible that changes in these factors may cause significant changes in the estimated useful lives of the Company’s property, plant and equipment in the future. ii) Biological asset The fair value of the biological asset is derived using a discounted cash flow model. Management estimates the sales price of produce on the vine by utilizing actual sales prices for the first six weeks following the end of the reporting period and estimates the costs to sell and complete by projecting yields and crop, packaging, and transportation costs. The estimated costs are subject to fluctuations based on the timing of prevailing growing conditions and market conditions. Management has also used judgment in determining the point at which biological transformation has occurred to the point that they expect it is probable that future economic benefits associated with the crop will flow to the Company. iii) Inventories and cost of sales Cost of sales is based upon incurred costs, and estimated costs to be incurred, of each crop allocated to both actual and estimated future yields over each crop cycle. The estimates of future yields are reviewed at each reporting period for accuracy. However, numerous factors such as weather, diseases and prevailing market conditions can impact the estimation of pricing, costs, and future yields. The estimated costs to be incurred are based on references to historical costs and updated for discussions with suppliers and senior management. Inventories include the actual cost of the crop not yet defined as a biological asset, packaging supplies, and purchased produce, less the amounts that have been expensed in cost of sales. iv) Income taxes and deferred income tax assets or liabilities Management uses judgment and estimates in determining the appropriate rates and amounts in recording deferred taxes, giving consideration to timing and probability. Actual taxes could vary significantly from these estimates as a result of future events, including changes in income tax law or the outcome of reviews by tax authorities and related appeals. The resolution of these uncertainties and the associated final taxes may result in adjustment to the Company’s tax assets and tax liabilities. The recognition of deferred income tax assets is subject to judgment and estimation over whether these amounts can be realized.

Changes in Accounting Policies

Changes in Accounting Policies	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Changes in Accounting Policies	4 CHANGES IN ACCOUNTING POLICIES The Company has adopted the following new and revised standards and changes in accounting policies, along with any consequential amendments as at January 1, 2018. These changes were made in accordance with the applicable transitional provisions. IFRS 9, Financial Instruments Financial Instruments Recognition and Measurement de-recognition, Following the adoption of IFRS 9, the Company could no longer defer and amortize financing fees that resulted from the refinancing of borrowings in periods prior to January 1, 2018. As a result, the Company has restated the beginning balances noted in the table below to properly account for $260 of financing fees in accordance with IFRS 9. The standard was applied retrospectively therefore approximately $260 of deferred financing costs, net of accumulated amortization, remain netted against long-term debt on the consolidated statement of financial position, as at December 31, 2017. The following table shows the adjustments recognized for each individual line item. Statement of Financial Position (extract) December 31, 2017 As originally IFRS 9 January 1, 2018 Restated Non-current Long-term debt $ 35,760 $ 260 $ 36,020 Total liabilities 61,298 260 61,558 Shareholders’ Equity Retained earnings 39,272 (260 ) 39,012 Total shareholders’ equity $ 81,043 $ (260 ) $ 80,783 IFRS 15, replaces IAS 18, Revenue Construction Contracts The Company generates its revenue through the sale of produce, with standard shipping terms and discounts, and through the production and sale of power. The Company’s produce revenue transactions consist of single performance obligations to transfer promised goods. Quantities to be delivered to the customer are determined at a point near the date of delivery through purchase orders it receive from the customer. The Company recognizes revenue when it has fulfilled a performance obligation, which is typically when the customer receives the goods and its performance obligation is complete. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring product. The amount of revenue recognized is reduced for estimated returns and other customer credits, such as discounts and rebates, based on the expected value to be realized. Payment terms are consistent with terms standard to the markets the Company serves. The Company maintains an allowance for doubtful accounts for the loss that would be incurred if a customer was unable to pay amounts due. The Company initially estimates the allowance required at the time of revenue recognition based on historical experience and makes changes to the allowance based on various factors, including changes in the customer’s financial condition or payment patterns. The Company sells electricity to British Columbia Hydro and Power Authority. Revenues are recognized as the electricity is delivered to/consumed by the customer and is based on contractual usage rates and meter readings that measure electricity consumption. The Company adopted IFRS 15, as of January 1, 2018, using the modified retrospective transition method, which involves not restating periods prior to the date of initial application. The application of IFRS 15 required no change in amounts recognized in the Company’s consolidated financial statements for the year ended December 31, 2018, as the amount and timing of substantially all of its revenues is, and will continue to be, recognized at delivery. Disclosures required by IFRS 15 have been included in the financial statements. Accounting Standards Issued But Not Yet Adopted IFRS 16, Leases Leases, right-of-use right-of-use low-value right-of-use Amendments to IFRS 11, Joint Arrangements Investments in Associates and Joint Ventures

Inventories

Inventories	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Inventories	5 INVENTORIES December 31, 2018 December 31, 2017 Deferred crop costs $ 24,649 $ 19,070 Purchased produce inventory 643 396 Biological asset adjustment (note 6) (2,871 ) (2,212 ) Spare parts inventory 64 55 $ 22,485 $ 17,309 The cost of inventories recognized as expense and included in cost of sales for the year ended December 31, 2018 amounted to $114,236 (2017 - $120,509). The biological asset adjustment reclassifies actual costs incurred for the biological asset from inventories to biological asset on the consolidated statements of financial position.

Biological Asset

Biological Asset	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Biological Asset	6 BIOLOGICAL ASSET Information about the biological asset presented on the consolidated statements of financial position and in the consolidated statements of (loss) income is as follows: December 31, 2018 December 31, 2017 Estimated sales value - biological asset $ 8,004 $ 7,937 Less Estimated remaining costs to complete 3,304 3,043 Estimated selling costs 470 489 Fair value of biological asset less costs to sell 4,230 4,405 Less actual costs (note 5) 2,871 2,212 Increase in fair value of biological asset over cost 1,359 2,193 Fair value over cost of harvested and sold biological asset - beginning of year 2,193 1,928 Change in biological asset $ (834 ) $ 265

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Property, Plant and Equipment	7 PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment consist of the following: Land Leasehold Buildings Machinery Construction Total Year ended December 31, 2017 Opening net book value $ 11,864 $ 1,692 $ 50,517 $ 31,767 $ 295 $ 96,135 Additions/transfers — — (416 ) 789 1,412 1,785 Additions-Capital Lease — — — 191 — 191 Placed in service — — — 1,071 (1,164 ) (93 ) Disposals (2,752 ) — (5,524 ) (4,694 ) (75 ) (13,045 ) Accum deprec on disposal — — 1,601 2,521 — 4,122 Depreciation expense — (95 ) (2,858 ) (4,633 ) — (7,586 ) Foreign currency translation adjustment — — 24 221 — 245 Closing net book value $ 9,112 $ 1,597 $ 43,344 $ 27,233 $ 468 $ 81,754 At December 31, 2017 Cost $ 9,112 $ 3,820 $ 77,029 $ 63,237 $ 468 $ 153,666 Accumulated depreciation — (2,223 ) (33,685 ) (36,004 ) — (71,912 ) Net book value $ 9,112 $ 1,597 $ 43,344 $ 27,233 $ 468 $ 81,754 Year ended December 31, 2018 Opening net book value $ 9,112 $ 1,597 $ 43,344 $ 27,233 $ 468 $ 81,754 Additions/transfers — — 3,012 3,116 6,128 Placed in service — — — (3,035 ) (3,035 ) Disposals (65 ) — — (565 ) — (630 ) Accum deprec on disposal — — — 565 — 565 Depreciation expense — (85 ) (2,604 ) (4,338 ) — (7,027 ) Foreign currency translation adjustment — — (26 ) (253 ) 3 (276 ) Closing net book value $ 9,047 $ 1,512 $ 40,714 $ 25,654 $ 552 $ 77,479 At December 31, 2018 Cost $ 9,047 $ 3,820 $ 77,003 $ 65,996 $ 552 $ 156,418 Accumulated depreciation — (2,308 ) (36,289 ) (40,342 ) — (78,939 ) Net book value $ 9,047 $ 1,512 $ 40,714 $ 25,654 $ 552 $ 77,479 Depreciation related to the greenhouse facilities and equipment is expensed in cost of sales. Land is the only item of property, plant and equipment that is stated at fair values. As at December 31, 2017, land, greenhouse buildings, and greenhouse equipment at Delta 3 were contributed as the Company’s investment in the joint venture transaction (note 8). The revaluation surplus related to Delta 3 of $1.8 million, net of taxes, that was previously recorded as a component of equity, was reclassified and included as part of the gain on disposal of assets recorded in the consolidated statements of (loss) income .

Investment in Joint Venture

Investment in Joint Venture	12 Months Ended
	Dec. 31, 2018
Investments accounted for using equity method [abstract]
Investment in Joint Venture	8 INVESTMENT IN JOINT VENTURE On June 6, 2017, the Company entered into an agreement to form Pure Sunfarms Corp. (“Pure Sunfarms”), a B.C. corporation, with Emerald Health Therapeutics Inc. (“Emerald”). The purpose of Pure Sunfarms is to pursue large-scale cannabis production in Canada. Village Farms has a 50% ownership interest in Pure Sunfarms in the form of common shares. The Company has concluded that the agreement constitutes a joint arrangement where joint control is shared with Emerald and therefore has accounted for Pure Sunfarms in accordance with IFRS 11 and IAS 28, using the equity method. In conjunction with the formation of Pure Sunfarms, Village Farms contributed the rights to lease and purchase the Delta 3 land and greenhouse facility to the joint venture. The contribution of the rights has been accounted for as a reduction of the land and greenhouse facility in exchange for the investment in Pure Sunfarms Corp. It was determined that the land and greenhouse facility had a fair value of $14.9 million (CA$20 million) at the date of contribution. The fair value of the land was determined through an appraisal performed by an independent valuator. The fair value of the greenhouse was determined using the replacement cost model adjusted for the age of the greenhouse. This was a non-cash As part of the transaction, Village Farms incurred related transaction costs of $1.1 million (CA$1.4 million), which have been added to the amount of the investment in Pure Sunfarms Corp. in accordance with IAS 28. Included in these costs are 300,000 common share purchase warrants valued at $148 (CA$192), issued to an affiliate of a Canadian financial institution as partial consideration for services related to the joint venture agreement. As at December 31, 2018 the Investment in Joint Venture of $18.1 million (December 31, 2017—$15.7 million) is recorded in the consolidated statement of financial position. For the year ended December 31, 2018, the Company’s share of net income from joint venture totaled $2,381 (CA$3,084) (2017—$255), which is recorded in the consolidated statement of loss. On July 5, 2018, the Company and Emerald Health Therapeutics Canada Inc. (a subsidiary of Emerald) (together, the “Shareholders”) entered into a Shareholder Loan Agreement (the “Loan Agreement”) with Pure Sunfarms, whereby, as at December 31, 2018, the Shareholders had each contributed CA$13,000 (US$9,959) the form of a demand loan to Pure Sunfarms. The loan amounts will initially bear simple interest at the rate of 8% per annum, calculated semi-annually. Interest will accrue and be payable upon demand being made by both Shareholders (see note 13). The Company’s share of the joint venture consists of the following (in $000’s of USD): Balance, January 1, 2018 $ 15,727 Share of income for the year 2,381 Balance, December 31, 2018 $ 18,108 Summarized financial information of Pure Sunfarms (in $000’s of CAD): December 31, 2018 December 31, 2017 Current assets Cash and cash equivalents $ 2,362 $ 2,907 Trade receivables 1,312 — Inventory 8,356 25 Biological asset 7,388 — Other current assets 996 210 Non-current 67,263 23,384 Current liabilities Trade payables (9,361 ) (253 ) Due to joint venture partners (26,523 ) — Other current liabilities (3,582 ) (918 ) Non-current (2,688 ) — Net assets $ 45,523 $ 25,355 December 31, 2018 December 31, 2017 Reconciliation of net assets: Accumulated deficit $ 5,523 $ (645 ) Contributions from joint venture partners 40,000 26,000 Net assets $ 45,523 $ 25,355 Year Ended Year Ended Revenue $ 4,917 $ — Cost of sales* (1,542 ) — Selling, general and administrative expenses (3,386 ) (880 ) Change in fair value of bio-asset 8,785 — Income (loss) from operations 8,774 (880 ) Interest expense, net (97 ) — Foreign exchange loss (234 ) (4 ) Other income, net 24 — Income (loss) before taxes 8,467 (884 ) (Provision for) recovery of income taxes (2,298 ) 239 Net income (loss) $ 6,169 $ (645 ) * Included in cost of sales is CA$276 (US$206) of amortization expense.

Other Assets

Other Assets	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Other Assets	9 OTHER ASSETS The following table summarizes the components of other assets: December 31, 2018 December 31, 2017 Patronage stock $ 386 $ 437 Note receivable (note 13) 64 70 Security deposits 540 538 Cash surrender value—insurance 929 924 Other 288 35 Total $ 2,207 $ 2,004

Debt

Debt	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Debt	10 DEBT December 31, 2018 December 31, 2017 Long-term debt: Opening balance $ 38,380 $ 45,534 IFRS adjustment for deferred financing fees 260 Proceeds from long-term debt — 306 Repayment of debt (2,738 ) (7,320 ) Foreign currency translation (43 ) 120 Closing balance $ 35,859 $ 38,640 Current portion $ 3,414 $ 2,620 Non-current 32,445 36,020 Less: Unamortized deferred transaction costs — (260 ) $ 35,859 $ 38,380 The Company has a Term Loan financing agreement with a Canadian creditor (“FCC Loan”). The non-revolving The Company’s subsidiary VFCE has a loan agreement with a Canadian Chartered Bank that includes a non-revolving non-revolving The Company has a line of credit agreement with a Canadian Chartered Bank ( “Operating Loan”). The revolving Operating Loan has a line of credit up to CA$13,000 and variable interest rates with a maturity date on May 31, 2021, and is subject to margin requirements stipulated by the bank. As at December 31, 2018, US$2,000 was drawn on this facility (December 31, 2017 - $nil), which is available to a maximum of CA$13,000, less outstanding letters of credit totaling US$261 and CA$38. The Company’s borrowings (“Credit Facilities”) are subject to certain positive and negative covenants. As at December 31, 2018 the Company was in compliance with all covenants on its Credit Facilities with the exception of two of its FCC Loan covenants. The Company received a waiver for its Debt Service Coverage and Debt to EBITDA covenants as at December 31, 2018. Accrued interest payable on the credit facilities and loans as at December 31, 2018 was $184 (December 31, 2017—$193) and these amounts are included in accrued liabilities in the statement of financial position. As security for the FCC Loan, the Company has provided promissory notes, a first mortgage on the VFF-owned As security for the Operating Loan, the Company has provided promissory notes and a first priority security interest over its accounts receivable and inventory. In addition, the Company has granted full recourse guarantees and security therein. The carrying value of the assets pledged as collateral as at December 31, 2018 was $38,007 (December 31, 2017—$32,883). The aggregate annual maturities of long-term debt for the next five years and thereafter are as follows: 2019 $ 3,414 2020 3,409 2021 28,551 2022 330 2023 155 Thereafter — $ 35,859

Commitments

Commitments	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Commitments	11 COMMITMENTS Operating Leases The Company has entered into certain operating lease commitments for land, office space and equipment through 2024. The future minimum lease payments for the next five years and thereafter are as follows: 2019 $ 1,253 2020 1,039 2021 1,052 2022 841 2023 618 Thereafter 261 $ 5,064 The Company made payments of $1,732 during the year ended December 31, 2018 (2017 - $1,682). Payments include common area amounts and fees paid to the lessors.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Financial Instruments	12 FINANCIAL INSTRUMENTS The following table summarizes the carrying and fair value of the Company’s financial instruments: December 31, 2018 December 31, 2017 Cash and cash equivalents $ 11,920 $ 7,091 Trade receivables $ 11,292 $ 11,259 Other financial assets $ 11,659 $ 2,491 Other financial liabilities $ 57,198 $ 56,718 Financial assets and liabilities are recognized on the consolidated statements of financial position at fair value in a hierarchy that is based on significance of the inputs used in making the measurements. The levels in the hierarchy are: • Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities • Level 2 - Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices) • Level 3 - Inputs for the asset or liability that are not based on observable market data (i.e., unobservable inputs). At December 31, 2018 and 2017, the Company’s financial instruments included cash and cash equivalents, trade receivables, notes receivable, other receivables, patronage stock, accounts payable, other current liabilities and notes payable. Due to the short-term maturities of cash and cash equivalents, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate fair value at the respective balance sheet dates. The carrying value of the notes receivable and notes payable approximate their fair value based on a comparison with the prevailing market interest rates. The fair values of the Company’s notes receivable and notes payable are level 2 measurements in the fair value hierarchy. All other financial assets and liabilities are level 1. None were classified as level 3. There were no financial instruments categorized as Level 2 or 3 as at December 31, 2018 and 2017. There were no transfers of assets or liabilities between levels during the years ended December 31, 2018 and 2017. Interest income, expense and gains and losses from loans, receivables and other financial liabilities are recognized in the consolidated statements of (loss) income. The following table summarizes interest income and expense for the years ended December 31: 2018 2017 Interest income earned on cash and cash equivalents $ 311 $ — Interest expense from other financial liabilities $ 2,718 $ 2,695 Management of financial risks The Company, through its financial assets and liabilities, is exposed to various risks. The following provides a measurement of some of these risks as at December 31, 2018 and 2017. The Company uses financial instruments only for risk management purposes, not for generating trading profit. i) Credit risk Credit risk is the risk that the Company will incur a loss due to the failure by its customers or other parties to meet their contractual obligations. Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, trade receivables and other receivables. The Company limits its exposure to credit risk by placing its cash and cash equivalents with high credit quality financial institutions. The Company’s trade receivables had two customers that represented more than 10% of the balance of trade receivables, representing 13.8% and 11.5% of the balance of trade receivables as at December 31, 2018 (2017 - two customers represented 16.0% and 14.8%). The Company believes that its expected credit losses are limited due to the protection afforded to the Company by the Perishable Agricultural Commodities Act As at December 31, 2018, the allowance for doubtful accounts balance was calculated based on the expected credit loss model and expected credit losses continues to be insignificant. At December 31, 2018, 90.3% (2017 - 89.4%) of trade receivables were outstanding less than 30 days, 8.3% (2017 – 7.4%) were outstanding for between 30 and 90 days and the remaining 1.4% (2017 - 3.2%) were outstanding for more than 90 days. Trade receivables are considered past due based on the contract terms agreed to with a customer. Aged receivables that are past due are not considered impaired unless customer specific information indicates otherwise. ii) Interest rate risk Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk on its long-term debt, for which the interest rates charged fluctuate based on the 90-day iii) Foreign exchange risk At December 31, 2018, the Canadian/U.S. foreign exchange rate was CA$1.00 = US$0.7336 (2017 – US$0.7966). Assuming that all other variables remain constant, an increase of $0.10 in the Canadian dollar would have the following impact on the ending balances of certain consolidated statements of financial position items at December 31, 2018 and December 31, 2017 with the net foreign exchange gain or loss directly impacting net income (loss) for the years. December 31, 2018 December 31, 2017 Financial assets Cash and cash equivalents $ 839 $ 287 Trade receivables 328 349 JV Note receivable 1,335 Financial liabilities Trade payables and accrued liabilities (373 ) (371 ) Loan payable (193 ) (232 ) Net foreign exchange gain (loss) $ 1,936 $ 33 iv) Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its obligations as they fall due. The following are the contractual maturities of financial liabilities as at December 31, 2018: Financial liabilities Total 1 year 2-3 4-5 More than Long-term debt $ 38,588 $ 3,698 $ 34,296 $ 594 $ — Line of credit 2,000 2,000 — — — Trade payables 14,601 14,601 — — — Accrued liabilities 3,509 3,509 — — — Obligation under capital lease 180 78 92 10 — Other liabilities 1,050 — 1,050 — — Total $ 59,928 $ 23,886 $ 35,438 $ 604 $ — It is the Company’s intention to meet these obligations through the collection of current accounts receivable and cash from sales. If the current resources and cash generated from operations are insufficient to satisfy its obligations, the Company may seek to issue additional equity or to arrange debt or other financing. In addition, as at December 31, 2018, the Company has an operating credit facility of up to CA$13,000, less outstanding letters of credit totaling US$261 and CA$38. v) Fair values The carrying amount of short-term financial instruments, less provisions for impairment if applicable, is consistent with the fair value of such instruments. The Company’s debt bears a variable interest rate tied to market rates and therefore its carrying value approximates its fair value.

Related Party Transactions and

Related Party Transactions and Balances	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Related Party Transactions and Balances	13 RELATED PARTY TRANSACTIONS AND BALANCES As at December 31, 2018, the Company had amounts due from its joint venture, Pure Sunfarms, totaling $1,079 (December 31, 2017 - $411) primarily for consulting services and the reimbursement of expenses which occurred in the year. These amounts were non-interest One of the Company’s employees is related to a member of the Company’s executive management team and received $108 in salary and benefits during the year ended December 31, 2018 (2017 - $98). Included in other assets as at December 31, 2018 is a $64 (December 31, 2017 - $70) promissory note that represents the unpaid amount the Company advanced to an employee in connection with a relocation at the request of the Company.

Compensation of Key Management

Compensation of Key Management	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Compensation of Key Management	14 COMPENSATION OF KEY MANAGEMENT Key management includes the Company’s officers and vice presidents: Year Ended Year Ended Salaries and other employee benefits $ 2,184 $ 1,778 Share-based payments 629 1,104 $ 2,813 $ 2,882

Expenses by Nature

Expenses by Nature	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Expenses by Nature	15 EXPENSES BY NATURE The following table outlines the Company’s significant expenses by nature: Cost of sales Year Ended Year Ended Purchased produce $ 44,110 $ 41,978 Raw materials and consumables used 32,096 40,365 Depreciation and amortization 6,911 7,447 Transportation and storage 21,074 19,999 Employee compensation and benefits 36,091 34,644 $ 140,282 $ 144,433 Selling, general and administrative expenses Year Ended Year Ended Employee benefits - salaries and short-term benefits $ 8,360 $ 8,422 Employee benefits - share-based payments 1,454 1,519 Marketing 504 617 Professional services 2,120 1,705 Office expenses 1,680 1,671 Other 1,444 1,479 $ 15,562 $ 15,413 Employee compensation and benefits Year Ended Year Ended Salaries and short-term employee benefits $ 44,451 $ 43,066 Share-based compensation 1,454 1,519 $ 45,905 $ 44,585

Income Tax Expense

Income Tax Expense	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Income Tax Expense	16 INCOME TAX EXPENSE The provision for (recovery of) income taxes consists of the following components: Year Ended Year Ended Current $ 431 $ 29 Deferred (2,906 ) 109 Provision for (recovery of) income taxes $ (2,475 ) $ 138 The provision for (recovery of) income taxes reflected in the consolidated statements of (loss) income for the years ended December 31, 2018 and December 31, 2017 differs from the amounts computed at the federal statutory tax rates. The principal differences between the statutory income tax (recovery) and the effective provision for (recovery of) income taxes are summarized as follows: Year Ended Year Ended Income (loss) before income taxes $ (7,620 ) $ 3,960 Tax (recovery) calculated at domestic tax rates applicable in the respective countries (1,595 ) 674 Non-deductible 394 422 True up of prior year income tax estimates (206 ) — Tax rate differences on deferred taxes — (482 ) State tax adjustments — (36 ) Foreign exchange on translation — 132 Unrealized foreign exchange (309 ) 116 Differences attributed to joint venture capital transactions (56 ) (698 ) Share of (income) losses from joint venture (611 ) 66 Other (92 ) (56 ) Provision for (recovery of) income taxes $ (2,475 ) $ 138 The statutory tax rate in effect for the year ended December 31, 2018 was 27.0% (2017 - 26.0%) in Canada and 21.0% (2017 - 23.0%) in the United States. As a result of the US tax reform, the US federal tax rate was substantively enacted on December 22, 2017 and a reduced federal tax rate was effective from January 1, 2018 in accordance with the Tax Cuts and Jobs Act of 2017. Accordingly, the relevant deferred tax balances were re-measured The weighted average applicable tax rate was 32.3% tax benefit for 2018 (2017 – 3.5%).

Deferred Income Taxes

Deferred Income Taxes	12 Months Ended
	Dec. 31, 2018
Subclassifications of assets, liabilities and equities [abstract]
Deferred Income Taxes	17 DEFERRED INCOME TAXES The deferred tax assets and liabilities presented on the consolidated statements of financial position are net amounts corresponding to their reporting jurisdiction. The deferred tax assets and liabilities presented in the note disclosure are grouped based on asset and liability classification without consideration of their corresponding reporting jurisdiction. The amounts in the consolidated statements of financial position reconcile to the amounts disclosed in this note as follows: December 31, 2018 December 31, 2017 Deferred tax assets $ 9,599 $ 7,606 Deferred tax liabilities (11,519 ) (12,431 ) $ (1,920 ) $ (4,825 ) Deferred tax assets: Tax losses/ LT Debt/ Inventory Intangibles Other Total At January 1, 2017 $ 7,413 $ 3,190 $ 518 $ 399 $ 437 $ 11,957 Charged to statement of income (loss) (2,289 ) (968 ) (144 ) (399 ) (551 ) (4,351 ) At December 31, 2017 $ 5,124 $ 2,222 $ 374 $ — $ (114 ) $ 7,606 Credited (charged) to statement of (loss) income 1,053 524 133 — 283 1,993 At December 31, 2018 $ 6,177 $ 2,746 $ 507 $ — $ 169 $ 9,599 Deferred tax liabilities: Accelerated Biological Revaluation Joint Total At January 1, 2017 $ (15,205 ) $ (674 ) $ (1,065 ) $ — $ (16,944 ) Credited (charged) to statement of income (loss) 6,179 214 — (2,151 ) 4,242 Charged to statements of other comprehensive (loss) income — — 271 — 271 At December 31, 2017 $ (9,026 ) $ (460 ) $ (794 ) $ (2,151 ) $ (12,431 ) Credited to statement of (loss) income 567 175 — 170 912 At December 31, 2018 $ (8,459 ) $ (285 ) $ (794 ) $ (1,981 ) $ (11,519 ) The analysis of deferred tax assets and deferred tax liabilities is as follows: December 31, 2018 December 31, 2017 Canada U.S. Canada U.S. Deferred tax assets: Expected to be recovered in more than 12 months $ 1,155 $ 7,465 $ 747 $ 5,753 Expected to be recovered within 12 months 312 667 388 718 Deferred tax liabilities: Expected to be settled in more than 12 months (4,181 ) (6,251 ) (4,606 ) (6,569 ) Expected to be settled within 12 months (41 ) (1,046 ) (40 ) (1,216 ) Deferred tax liabilities, net of assets $ (2,755 ) $ 835 $ (3,511 ) $ (1,314 ) Non-capital Canada U.S. Total 2021 $ — $ 8,402 $ 8,402 2022 — 5,043 5,043 2023 — 5,117 5,117 2024 — 4,015 4,015 2025 — 8,757 8,757 2027 25 — 25 2028 4 — 4 2029 25 64 89 2030 7 — 7 2031 4 988 992 2032 4 14,895 14,899 2033 4 — 4 2034 4 11,665 11,669 2035 108 7,445 7,553 2036 98 3,583 3,681 2037 98 5,570 5,668 2038 4 9,325 9,329 $ 385 $ 84,869 $ 85,254 Deferred income tax assets are recognized for tax loss carry-forwards to the extent that the realization of the related tax benefit through future profits is probable.

Changes in Non-cash Working Cap

Changes in Non-cash Working Capital Items	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Changes in Non-cash Working Capital Items	18 CHANGES IN NON-CASH For the Years Ended December 31, 2018 2017 Trade receivables $ (46 ) $ (1,059 ) Inventories (5,180 ) (1,197 ) Inventories reclassified to biological asset (659 ) 306 Other receivables 172 (1,396 ) Income taxes payable 68 (246 ) Prepaid expenses and deposits 734 41 Trade payables 1,440 394 Accrued liabilities (121 ) (955 ) Other assets, net of other liabilities 42 (305 ) $ (3,550 ) $ (4,417 )

Segment and Geographic Informat

Segment and Geographic Information	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Segment and Geographic Information	19 SEGMENT AND GEOGRAPHIC INFORMATION The Company’s two reporting segments include the Produce business and the Energy business. The Produce business produces, markets, and sells the product group which consists of premium quality tomatoes, bell peppers and cucumbers. The Energy business produces power that it sells per a long-term contract to its one customer. The Company’s primary operations are in the United States and Canada. Net sales by the countries in which its customers are located are as follows: For the Years Ended December 31, 2018 2017 Sales Produce - U.S. $ 124,699 $ 132,464 Produce - Canada 23,355 24,020 Energy - Canada 1,946 1,922 $ 150,000 $ 158,406 The Company’s property, plant and equipment, net of accumulated depreciation, are located as follows: December 31, 2018 December 31, 2017 United States $ 43,651 $ 46,922 Canada 30,459 31,183 Energy - Canada 3,369 3,649 $ 77,479 $ 81,754 The depreciation and amortization charges for the year ended December 31, 2018 in the Produce business were $6,154 (2017 - $6,791) and $873 (2017 - $795) in the Energy business.

Share Capital and Equity

Share Capital and Equity	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Share Capital and Equity	20 SHARE CAPITAL AND EQUITY The following is a summary of share capital: The VFF Common Shares # of Shares Amount Share capital - January 1, 2017 38,882,945 $ 24,954 Shares issued pursuant to public offering, net 2,500,000 9,769 Shares issued from vesting of RSUs 768,000 1,333 Shares issued on exercise of options 91,667 59 Share capital - December 31, 2017 42,242,612 36,115 Shares issued pursuant to public offering, net 3,097,200 15,737 Shares issued pursuant to private placement, net 1,886,793 7,755 Shares issued from vesting of RSUs 50,334 831 Shares issued on exercise of options 365,732 283 Share capital - December 31, 2018 47,642,671 $ 60,721 VFF is authorized to issue an unlimited number of common shares and preferred shares, issuable in series. These shares have no par value. (i) Common shares: The common shares entitle the holders thereof to one vote per share at all shareholder meetings of VFF. The holders of the common shares are entitled to receive any dividend declared by VFF on the common shares. Subject to the rights, privileges, restrictions and conditions attached to any other class of shares of VFF, the holders of the common shares are entitled to receive, pro rata, the remaining property or assets of VFF upon its dissolution, liquidation or wind-up. (ii) Preferred shares: The preferred shares may be issued in one or more series, with such rights and conditions as may be determined by resolution of the directors of VFF who shall determine the designation, rights, privileges, conditions and restrictions to be attached to the preferred shares of such series. There are no voting rights attached to the preferred shares except as prescribed by law. In the event of the liquidation, dissolution or wind-up

Income Per Share

Income Per Share	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Income Per Share	21 INCOME PER SHARE Basic income per share is calculated by dividing the net income attributable to owners of the Company by the weighted average number of common shares in issue during the year excluding common shares purchased by the Company and held as treasury shares. For the Years Ended December 31, 2018 2017 Net income (loss) attributable to owners of the Company $ (5,145 ) $ 3,822 Weighted average number of common shares outstanding (thousands) 44,357 39,144 Basic income (loss) per share $ ( 0.11 ) $ 0.10 Diluted income per share is calculated by adjusting the weighted average number of common shares outstanding to assume conversion of all dilutive potential common shares. The Company’s share options are potentially dilutive to common shares. A calculation is done to determine the number of shares that could have been acquired at fair value (determined as the average market share price of the Company’s shares for the year) based on the monetary value of the subscription rights attached to outstanding share options. The number of shares calculated above is compared with the number of shares that would have been issued assuming the exercise of the share options. If dilutive effect is less than zero, then issuance is anti-dilutive and is excluded from dilutive income per share calculation. For the year ended December 31, 2018, there were options to purchase 2,175 (2017 - nil) shares of the Company’s common stock that were excluded from the diluted loss per share computation because the impact of the assumed exercise of such stock options would have been anti-dilutive during the respective periods. For the Years Ended December 31, 2018 2017 Net income (loss) attributable to owners of the Company $ (5,145 ) $ 3,822 Weighted average number of common shares outstanding (thousands) 44,357 39,144 Adjustment for: Share options (thousands) — 1,164 Weighted average number of common shares outstanding for diluted income per share (thousands) 44,357 40,308 Diluted income (loss) per share $ (0.11 ) $ 0.10

Capital Disclosures

Capital Disclosures	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Capital Disclosures	22 CAPITAL DISCLOSURES The Company’s objectives when managing capital are to safeguard its assets and maintain a competitive cost structure, continue as a going concern and provide returns to its shareholders. In addition, the Company works with all relevant stakeholders to ensure the safety of its operations and employees and remain in compliance with all environmental regulations. The Company’s main objectives when managing capital are: • to structure the repayment of obligations in line with the expected lives of the Company’s principal revenue generating assets; • to ensure the Company has access to capital to fund contractual obligations as they become due and to ensure adequate cash levels to withstand the impact of unfavorable economic conditions; • to maintain the Company’s credit ratings to facilitate access to capital markets at competitive interest rates; and • to access capital markets to fund its growth initiatives. The Company’s capital comprises net debt and equity: December 31, 2018 December 31, 2017 Total bank debt $ 37,859 $ 38,640 Less cash and cash equivalents (11,920 ) (7,091 ) Net debt 25,939 31,549 Total equity 100,696 81,043 $ 126,635 $ 112,592 It is the Company’s intention to meet its obligations through the collection of current accounts receivable and cash. As at December 31, 2018, the Company has access to an operating loan facility up to CA$13,000, less $261 and CA$38 outstanding letters of credit. As at December 31, 2018, $2,000 was outstanding on the operating loan (as at December 31, 2017, $nil was outstanding on the operating loan, and $261 and CA$38 outstanding on the letters of credit). As at December 31, 2018, the operating loan borrowing base was CA$11,509 based on a percentage of the Company’s outstanding accounts receivable less the issued letters of credit. If the current resources and cash generated from operations are insufficient to satisfy its obligations, the Company may seek to issue additional equity or to arrange debt or other financing.

Share-Based Compensation Plan

Share-Based Compensation Plan	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Share-Based Compensation Plan	23 SHARE-BASED COMPENSATION PLAN The Company has a share-based compensation plan. The maximum number of common shares that can be issued upon the exercise of options granted is equal to 10% of the aggregate number of common shares issued and outstanding from time to time. The term during which an option may be exercised is 10 years from the date of the grant. Options vest at a rate of 33% per year, beginning one year following the grant date of the options. Share-based The following table presents the assumptions used to establish the fair value assigned to the options issued using the Black-Scholes 2018 2017 Expected volatility 55.5 % 52.7 % Dividend $ nil $ nil Risk-free 2.70 % 2.05 % Expected life 6.5 years 6.5 years Fair value $ 3.2541 $ 3.1869 The changes in the stock options for the years ended December 31, 2018 and 2017 were as follows: For the Years Ended December 31, 2018 2017 Stock options Weighted Stock options Weighted Beginning of year 2,337,732 CA$ 1.59 2,116,065 CA$ 1.19 Granted 203,000 CA$ 5.79 320,000 CA$ 4.04 Exercised (365,733 ) CA$ 0.98 (91,667 ) CA$ 0.90 Forfeitures (10,000 ) CA$ 1.48 (6,666 ) CA$ 1.48 End of year 2,164,999 CA$ 2.10 2,337,732 CA$ 1.59 The following table summarizes stock options outstanding and granted as at December 31, 2018: Exercise price Number Remaining contractual Number of exercisable CA$1.24 425,000 2.4 425,000 CA$1.27 150,000 3.2 150,000 CA$0.85 100,000 4.2 100,000 CA$1.10 202,000 4.7 202,000 CA$1.48 345,000 5.2 345,000 CA$0.94 100,000 6.2 100,000 CA$0.83 20,000 6.8 20,000 CA$0.80 16,666 6.9 16,666 CA$1.43 233,333 7.3 150,002 CA$1.55 50,000 7.5 33,334 CA$2.20 165,000 8.5 54,999 CA$6.00 155,000 9.0 51,669 CA$5.79 203,000 9.6 Nil 2,164,999 Share options outstanding at the end of the year have the following expiry dates and exercise prices: Exercise price in CA$ December 31, December 31, Expiry date - January 13, 2020 0.70 — 149,399 Expiry date - May 20, 2021 1.24 425,000 565,000 Expiry date - March 13, 2022 1.27 150,000 150,000 Expiry date - March 13, 2023 0.85 100,000 100,000 Expiry date - September 26, 2023 1.10 202,000 215,000 Expiry date - March 18, 2024 1.48 345,000 360,000 Expiry date - March 19, 2025 0.94 100,000 100,000 Expiry date - October 6, 2025 0.83 20,000 28,333 Expiry date - November 16, 2025 0.80 16,666 50,000 Expiry date - March 29, 2026 1.43 233,333 250,000 Expiry date - June 30, 2026 1.55 50,000 50,000 Expiry date - June 14, 2027 2.20 165,000 165,000 Expiry date - December 22, 2027 6.00 155,000 155,000 Expiry date - June 5, 2028 5.79 203,000 — 2,164,999 2,337,732 During 2018, 979,000 performance-based restricted share units were issued to Village Farms employees involved with future developments of the Company. Once a performance target is met and the share units are deemed earned and vested, compensation expense based on the fair value of the share units on the grant date is recorded in selling, general and administrative expenses in the consolidated statements of income. There were 1,056,666 performance-based restricted share units outstanding as at December 31, 2018, of which 881,333 were not vested as at December 31, 2018. The following table summarizes 979,000 performance-based restricted share units that were issued during the year. 2018 2017 Performance- Weighted Performance- Weighted Beginning of year 128,000 CA$ 2.82 — Issued 979,000 CA$ 5.79 885,000 CA$ 2.20 Issued — 21,000 CA$ 6.00 Vested (50,334 ) CA$ 3.06 (768,000 ) CA$ 2.20 Expired — (10,000 ) CA$ 2.20 Outstanding at end of year 1,056,666 CA$ 5.56 128,000 CA$ 2.82 Earned but unissued at end of year 175,333 CA$ 5.08 —

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Subsequent Event	24 SUBSEQUENT EVENT On February 15, 2019 the Company announced that its common shares were approved for listing on the Nasdaq Capital Market under the symbol “VFF”. The initial trading date was February 21, 2019. Concurrent with the commencement of trading of its common shares on Nasdaq, the Company voluntarily delisted its common shares from the OTCQX. On March 1, 2019 the Company announced that it had entered into an agreement with Nature Crisp LLC (“Nature Crisp”) to form a joint venture for the outdoor cultivation of high-cannabidiol (CBD) hemp and CBD extraction in multiple states throughout the United States (the “Joint Venture Agreement”). The joint venture, Village Fields Hemp (“Village Fields”), will be 65% owned by Village Farms and 35% owned by Nature Crisp. Under the terms of the Joint Venture Agreement, Village Farms will contribute approximately US$15 million to Village Fields for start-up

Significant Accounting Polici_2

Significant Accounting Policies, Judgments and Estimation Uncertainty (Policies)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Consolidation	Consolidation The consolidated financial statements of the Company consolidate the accounts of VFF and its subsidiaries. All intercompany transactions, balances and unrealized gains and losses from intercompany transactions are eliminated on consolidation.
Joint Venture	Joint Venture A joint venture is a contractual arrangement whereby the Company and other parties undertake an economic activity through a jointly controlled entity. Joint control exists when strategic, financial and operating policy decisions relating to the activities require the unanimous consent of the parties sharing control. Joint ventures are accounted for using the equity method and are recognized initially at cost. The Company recognizes its share of the post-acquisition income and expenses and equity movement in the venture. If the cumulative losses exceed the carrying amount of the equity investment, they are first applied to any additional advances that are receivable from the joint venture to the extent of the total amount receivable. Additional losses are recognized only to the extent that there exists a legal or constructive obligation.
Segment Reporting	Segment Reporting Operating segments are reported in a manner consistent with internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer (“CEO”). Based on the aggregation criteria in IFRS 8, Operating Segments
Foreign Currency Translation	Foreign Currency Translation Monetary assets and liabilities denominated in foreign currencies are translated to the functional currency at the exchange rates in effect at the reporting date. Non-monetary Non-monetary
Financial Instruments	Financial Instruments Financial assets and liabilities are recognized when the Company becomes party to the contractual provisions of the financial instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Financial liabilities are derecognized when the obligation specified in the contract is discharged, cancelled or expired. Financial assets and liabilities are offset and the net amount is reported on the consolidated statements of financial position when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously. Classification and Measurement The Company has assessed the classification and measurement of its financial assets and financial liabilities under IFRS 9 and has summarized the original measurement categories under IAS 39 and the new measurement categories under IFRS 9 in the following table: Measurement Category Original (IAS 39) New (IFRS 9) Financial Assets: Cash Trade receivables Marketable equity securities Other financial assets Amortized cost Amortized cost Available-for-sale Amortized cost Amortized cost Amortized cost Fair value through other comprehensive income Amortized cost Financial Liabilities: Trade payables Debt Derivative instruments Other financial liabilities Amortized cost Amortized cost Fair value through profit or loss Amortized cost Amortized cost Amortized cost Fair value through profit or loss Amortized cost There has been no change in the carrying value of our financial instruments or to previously reported figures as a result of changes to the measurement categories in the table noted above.
Impairment of Financial Assets	Impairment of Financial Assets Prior to January 1, 2018, at each reporting date, the Company assessed whether there was objective evidence that a financial asset was impaired. The criteria used to determine if objective evidence of an impairment loss exists include: i) significant financial difficulty of the obligor; ii) delinquencies in interest or principal payments; and iii) it becomes probable that the borrower will enter bankruptcy or other financial reorganization. If such evidence existed, the Company recognized an impairment loss as follows: i) Financial assets carried at amortized cost: The loss equaled the difference between the amortized cost of the loan or receivable and the present value of the estimated future cash flows, discounted using the instrument’s original effective interest rate. The carrying amount of the asset was reduced by this amount either directly or indirectly through the use of an allowance account. ii) Available-for-sale Subsequent to January 1, 2018, the Company assesses all information available, including, on a forward-looking basis, the expected credit losses associated with its assets carried at amortized cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk. To assess whether there is a significant increase in credit risk, the Company compares the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date of initial recognition based on all information available, and reasonable and supportive forward-looking information. For trade receivables only, the Company applies the simplified approach as permitted by IFRS 9 which requires expected lifetime losses to be recognized from initial recognition of the receivables.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash deposits held with banks, and other highly liquid short-term interest bearing securities with maturities at the date of purchase of three months or less.
Trade Receivables	Trade Receivables Trade receivables are measured at amortized cost, net of allowance for expected credit losses. Credit is extended based on an evaluation of a customer’s financial condition. Accounts outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance by considering a number of factors, including the length of time accounts are past due, the Company’s previous loss history and the customer’s current ability to pay its obligation to the Company. Trade receivables are recorded net of lifetime expected credit losses.
Inventories	Inventories Inventories refer to deferred crop costs and other supplies and packaging which are incurred to date on current production and are not defined as a biological asset. Inventories of Company-grown produce consist of raw materials, labour and overhead costs incurred less costs charged to cost of sales throughout the various crop cycles, which end at various times throughout the year. Growing crops are accounted for in accordance with the Company’s policy on biological assets. Cost of sales is based on estimated costs over the crop cycle allocated to both actual and estimated future yields at each period-end The carrying value of agricultural produce is its fair value less costs to sell and complete at the date of harvest and is presented with biological asset on the consolidated statements of financial position. Supplies and packaging are recorded at the lower of cost or replacement cost. The cost of produce inventory purchased from third parties is valued at the lower of cost or net realizable value.
Biological Asset	Biological Asset Biological asset consists of the Company’s produce on the vines at year-end.
Property, Plant and Equipment	Property, Plant and Equipment Recognition and measurement Property, plant and equipment are stated at cost less accumulated depreciation and impairment losses, except for land. Until the fiscal year ended December 31, 2016, land had been stated at cost, and is now stated at fair value and will be revalued every three years by an independent external appraiser. Any revaluation increase arising on appraisal of land is recognized in other comprehensive income on the consolidated statements of (loss) income and revaluation surplus on the statements of financial position. Any revaluation decrease arising on appraisal of land is also charged to other comprehensive income and, to the extent of any credit balance existing, debited to revaluation surplus in equity with the excess recognized in net income or loss, Property, plant and equipment costs include expenditures that are directly attributable to the acquisition of the asset. The cost of self-constructed assets includes the cost of materials and direct labour, any other costs directly attributable to bringing the assets to a working condition for their intended use, the costs of dismantling and removing the items and restoring the site on which they are located, and borrowing costs. When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. The gain or loss on disposal of an item of property, plant and equipment is determined by comparing the proceeds from disposal with the carrying amount of the property, plant and equipment, and is presented net within gain/loss on disposal of assets in the consolidated statements of (loss) income. Depreciation Depreciation is based on the cost of an asset less its residual value. Significant components of individual assets are assessed, and if a component has a useful life that is different from the remainder of that asset, that component is depreciated separately. Depreciation expense is recognized on a straight-line basis over the estimated useful lives of each component of an item of property, plant and equipment. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. Land is not depreciated. The estimated useful lives of the class of assets for the current and comparative periods are as follows: Classification Estimated Useful Lives Leasehold and land improvements 5-20 Greenhouses and other buildings 4-30 Greenhouse equipment 3-30 Machinery and equipment 3-12 Construction in process reflects the cost of assets under construction, which are not depreciated until placed into service.
Impairment of Non-Financial Assets	Impairment of Non-Financial Property, plant and equipment and intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable. For the purpose of testing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units or “CGUs”). An impairment loss is recognized for the amount, if any, by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell and value in use (being the present value of the expected future cash flows of the relevant asset or CGUs).
Leased Assets	Leased Assets Leases where the Company assumes substantially all the risks and rewards of ownership are classified as finance leases. Upon initial recognition, the leased asset is measured at an amount equal to the lower of its fair value and the present value of the minimum lease payments. Subsequent to initial recognition, the asset is accounted for in accordance with the accounting policy applicable to that asset. Other leases are operating leases and rent expenses are recognized in the Company’s consolidated statements of (loss) income.
Borrowing Costs	Borrowing Costs Borrowing costs attributable to the acquisition, construction or production of qualifying assets are added to the cost of those assets, until such time as the assets are substantially ready for their intended use. All other borrowing costs are recognized initially at fair value. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the consolidated statements of (loss) income over the year of the borrowings using the effective interest method.
Revenue Recognition	Revenue Recognition Prior to January 1, 2018, revenue from the sale of produce in the course of ordinary activities was measured at the fair value of the consideration received or receivable, net of returns, trade discounts and volume rebates. Revenue from the production and sale of power was measured at the fair value of the consideration received or receivable. Revenue was recognized when persuasive evidence existed that the significant risks and rewards of ownership have been transferred to the customer, recovery of the consideration was probable, the associated costs and possible return of goods could be estimated reliably, there was no continuing management involvement with the goods, and the amount of revenue could be measured reliably. If it was probable that discounts would be granted and the amount could be measured reliably, then the discount was recognized as a reduction of revenue as the sales were recognized. The timing of the transfer of risks and rewards occurred at the time the produce had been successfully delivered, the risk of loss had passed to the customer, and collectability was reasonably assured. The Company adopted IFRS 15, Revenue from Contracts with Customers
Income Taxes	Income Taxes The tax expense for the year comprises current and deferred tax. Tax is recognized in the consolidated statements of (loss) income, except to the extent that it relates to items recognized in other comprehensive income or directly in equity. The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the consolidated statements of financial position dates in the relevant tax jurisdiction. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of the amounts expected to be paid to the tax authorities. Deferred income tax is recognized, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively enacted at the consolidated statements of financial position dates and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred income tax assets are recognized only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Offsetting of deferred income tax assets and liabilities occurs only when the deferred income tax assets and liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities where there is an intention to settle the balances on a net basis.
Share-Based Compensation	Share-Based Compensation The Company grants stock options and performance-based restricted share units (“RSUs”) to certain employees and directors. Stock options generally vest over three years (33% per year following the grant date) and expire after ten years. Each tranche in an award is considered a separate award with its own vesting period. The fair value of each tranche is measured at the date of grant using the Black-Scholes option pricing model. Compensation expense is recognized over the tranche’s vesting period by increasing contributed surplus based on the number of awards expected to vest. The number of awards expected to vest is reviewed at least annually, with any impact recognized immediately. The RSUs granted are expected to be settled using the Company’s own equity and issued from treasury. The equity-settled share-based compensation is measured at the fair value of the Company’s common shares as at the grant date in accordance with the terms of the RSU Plan. The fair value determined at the grant date is charged to income when performance based vesting conditions are met, based on the estimate of the number of RSUs that will eventually vest and be converted to common shares, with a corresponding increase in equity.
Provisions	Provisions Provisions, where applicable, are recognized in accrued liabilities when the Company has a present legal or constructive obligation as a result of past events, it is more likely than not that an outflow of resources will be required to settle the obligation, and the amount can be reliably estimated. Provisions are measured at management’s best estimate of the expenditure required to settle the obligation at the end of the reporting period, and are discounted to present value where the effect is material.
(Loss) Income Per Share	(Loss) Income Per Share Basic income per share are computed using the weighted average number of common shares outstanding during the period. The treasury stock method is used for the calculation of diluted income per share. Under this method, the weighted average number of common shares outstanding assumes that the proceeds to be received on the exercise of dilutive share options are applied to repurchase common shares at the average market price for the period. Share options are dilutive when the average market price of the common shares during the period exceeds the exercise price of the options.
Significant Accounting Judgments and Estimation Uncertainties	Significant Accounting Judgments and Estimation Uncertainties The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income, and expenses. These estimates and judgments have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities in future periods. Critical accounting estimates and judgments i) Estimated useful lives of property, plant and equipment Management estimates the useful lives of property, plant and equipment based on the period during which the assets are expected to be available for use. The amounts and timing of recorded expenses for depreciation of property, plant and equipment for any period are affected by these estimated useful lives. The estimates are reviewed at least annually and are updated if expectations change as a result of physical wear and tear, technical or commercial obsolescence and legal or other limits to use. It is possible that changes in these factors may cause significant changes in the estimated useful lives of the Company’s property, plant and equipment in the future. ii) Biological asset The fair value of the biological asset is derived using a discounted cash flow model. Management estimates the sales price of produce on the vine by utilizing actual sales prices for the first six weeks following the end of the reporting period and estimates the costs to sell and complete by projecting yields and crop, packaging, and transportation costs. The estimated costs are subject to fluctuations based on the timing of prevailing growing conditions and market conditions. Management has also used judgment in determining the point at which biological transformation has occurred to the point that they expect it is probable that future economic benefits associated with the crop will flow to the Company. iii) Inventories and cost of sales Cost of sales is based upon incurred costs, and estimated costs to be incurred, of each crop allocated to both actual and estimated future yields over each crop cycle. The estimates of future yields are reviewed at each reporting period for accuracy. However, numerous factors such as weather, diseases and prevailing market conditions can impact the estimation of pricing, costs, and future yields. The estimated costs to be incurred are based on references to historical costs and updated for discussions with suppliers and senior management. Inventories include the actual cost of the crop not yet defined as a biological asset, packaging supplies, and purchased produce, less the amounts that have been expensed in cost of sales. iv) Income taxes and deferred income tax assets or liabilities Management uses judgment and estimates in determining the appropriate rates and amounts in recording deferred taxes, giving consideration to timing and probability. Actual taxes could vary significantly from these estimates as a result of future events, including changes in income tax law or the outcome of reviews by tax authorities and related appeals. The resolution of these uncertainties and the associated final taxes may result in adjustment to the Company’s tax assets and tax liabilities. The recognition of deferred income tax assets is subject to judgment and estimation over whether these amounts can be realized.

Significant Accounting Polici_3

Significant Accounting Policies, Judgments and Estimation Uncertainty (Tables)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Schedule of Classification and Measurement of Financial Assets and Financial Liabilities Under Application of IFRS 9	The Company has assessed the classification and measurement of its financial assets and financial liabilities under IFRS 9 and has summarized the original measurement categories under IAS 39 and the new measurement categories under IFRS 9 in the following table: Measurement Category Original (IAS 39) New (IFRS 9) Financial Assets: Cash Trade receivables Marketable equity securities Other financial assets Amortized cost Amortized cost Available-for-sale Amortized cost Amortized cost Amortized cost Fair value through other comprehensive income Amortized cost Financial Liabilities: Trade payables Debt Derivative instruments Other financial liabilities Amortized cost Amortized cost Fair value through profit or loss Amortized cost Amortized cost Amortized cost Fair value through profit or loss Amortized cost
Summary of Estimated Useful Lives of Property Plant and Equipment	The estimated useful lives of the class of assets for the current and comparative periods are as follows: Classification Estimated Useful Lives Leasehold and land improvements 5-20 Greenhouses and other buildings 4-30 Greenhouse equipment 3-30 Machinery and equipment 3-12

Changes in Accounting Policies

Changes in Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Summary of Changes in Accounting Policies Adjustments Recognized for Each Individual Line Item	The following table shows the adjustments recognized for each individual line item. Statement of Financial Position (extract) December 31, 2017 As originally IFRS 9 January 1, 2018 Restated Non-current Long-term debt $ 35,760 $ 260 $ 36,020 Total liabilities 61,298 260 61,558 Shareholders’ Equity Retained earnings 39,272 (260 ) 39,012 Total shareholders’ equity $ 81,043 $ (260 ) $ 80,783

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Summary of Inventories	December 31, 2018 December 31, 2017 Deferred crop costs $ 24,649 $ 19,070 Purchased produce inventory 643 396 Biological asset adjustment (note 6) (2,871 ) (2,212 ) Spare parts inventory 64 55 $ 22,485 $ 17,309

Biological Asset (Tables)

Biological Asset (Tables)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Summary Of Biological Asset	Information about the biological asset presented on the consolidated statements of financial position and in the consolidated statements of (loss) income is as follows: December 31, 2018 December 31, 2017 Estimated sales value - biological asset $ 8,004 $ 7,937 Less Estimated remaining costs to complete 3,304 3,043 Estimated selling costs 470 489 Fair value of biological asset less costs to sell 4,230 4,405 Less actual costs (note 5) 2,871 2,212 Increase in fair value of biological asset over cost 1,359 2,193 Fair value over cost of harvested and sold biological asset - beginning of year 2,193 1,928 Change in biological asset $ (834 ) $ 265

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Summary of Property, Plant and Equipment	Property, plant and equipment consist of the following: Land Leasehold Buildings Machinery Construction Total Year ended December 31, 2017 Opening net book value $ 11,864 $ 1,692 $ 50,517 $ 31,767 $ 295 $ 96,135 Additions/transfers — — (416 ) 789 1,412 1,785 Additions-Capital Lease — — — 191 — 191 Placed in service — — — 1,071 (1,164 ) (93 ) Disposals (2,752 ) — (5,524 ) (4,694 ) (75 ) (13,045 ) Accum deprec on disposal — — 1,601 2,521 — 4,122 Depreciation expense — (95 ) (2,858 ) (4,633 ) — (7,586 ) Foreign currency translation adjustment — — 24 221 — 245 Closing net book value $ 9,112 $ 1,597 $ 43,344 $ 27,233 $ 468 $ 81,754 At December 31, 2017 Cost $ 9,112 $ 3,820 $ 77,029 $ 63,237 $ 468 $ 153,666 Accumulated depreciation — (2,223 ) (33,685 ) (36,004 ) — (71,912 ) Net book value $ 9,112 $ 1,597 $ 43,344 $ 27,233 $ 468 $ 81,754 Year ended December 31, 2018 Opening net book value $ 9,112 $ 1,597 $ 43,344 $ 27,233 $ 468 $ 81,754 Additions/transfers — — 3,012 3,116 6,128 Placed in service — — — (3,035 ) (3,035 ) Disposals (65 ) — — (565 ) — (630 ) Accum deprec on disposal — — — 565 — 565 Depreciation expense — (85 ) (2,604 ) (4,338 ) — (7,027 ) Foreign currency translation adjustment — — (26 ) (253 ) 3 (276 ) Closing net book value $ 9,047 $ 1,512 $ 40,714 $ 25,654 $ 552 $ 77,479 At December 31, 2018 Cost $ 9,047 $ 3,820 $ 77,003 $ 65,996 $ 552 $ 156,418 Accumulated depreciation — (2,308 ) (36,289 ) (40,342 ) — (78,939 ) Net book value $ 9,047 $ 1,512 $ 40,714 $ 25,654 $ 552 $ 77,479

Investment in Joint Venture (Ta

Investment in Joint Venture (Tables)	12 Months Ended
	Dec. 31, 2018
Investments accounted for using equity method [abstract]
Schedule of Joint Venture Share	The Company’s share of the joint venture consists of the following (in $000’s of USD): Balance, January 1, 2018 $ 15,727 Share of income for the year 2,381 Balance, December 31, 2018 $ 18,108
Summary Financial Information Joint Venture	Summarized financial information of Pure Sunfarms (in $000’s of CAD): December 31, 2018 December 31, 2017 Current assets Cash and cash equivalents $ 2,362 $ 2,907 Trade receivables 1,312 — Inventory 8,356 25 Biological asset 7,388 — Other current assets 996 210 Non-current 67,263 23,384 Current liabilities Trade payables (9,361 ) (253 ) Due to joint venture partners (26,523 ) — Other current liabilities (3,582 ) (918 ) Non-current (2,688 ) — Net assets $ 45,523 $ 25,355 December 31, 2018 December 31, 2017 Reconciliation of net assets: Accumulated deficit $ 5,523 $ (645 ) Contributions from joint venture partners 40,000 26,000 Net assets $ 45,523 $ 25,355 Year Ended Year Ended Revenue $ 4,917 $ — Cost of sales* (1,542 ) — Selling, general and administrative expenses (3,386 ) (880 ) Change in fair value of bio-asset 8,785 — Income (loss) from operations 8,774 (880 ) Interest expense, net (97 ) — Foreign exchange loss (234 ) (4 ) Other income, net 24 — Income (loss) before taxes 8,467 (884 ) (Provision for) recovery of income taxes (2,298 ) 239 Net income (loss) $ 6,169 $ (645 ) * Included in cost of sales is CA$276 (US$206) of amortization expense.

Other Assets (Tables)

Other Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Schedule of Components of Other Assets	The following table summarizes the components of other assets: December 31, 2018 December 31, 2017 Patronage stock $ 386 $ 437 Note receivable (note 13) 64 70 Security deposits 540 538 Cash surrender value—insurance 929 924 Other 288 35 Total $ 2,207 $ 2,004

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Summary of Debt	December 31, 2018 December 31, 2017 Long-term debt: Opening balance $ 38,380 $ 45,534 IFRS adjustment for deferred financing fees 260 Proceeds from long-term debt — 306 Repayment of debt (2,738 ) (7,320 ) Foreign currency translation (43 ) 120 Closing balance $ 35,859 $ 38,640 Current portion $ 3,414 $ 2,620 Non-current 32,445 36,020 Less: Unamortized deferred transaction costs — (260 ) $ 35,859 $ 38,380
Summary of Aggregate Annual Maturities of Long-Term Debt	The aggregate annual maturities of long-term debt for the next five years and thereafter are as follows: 2019 $ 3,414 2020 3,409 2021 28,551 2022 330 2023 155 Thereafter — $ 35,859

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Schedule of Future Minimum Lease Payment	The future minimum lease payments for the next five years and thereafter are as follows: 2019 $ 1,253 2020 1,039 2021 1,052 2022 841 2023 618 Thereafter 261 $ 5,064

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Summary of Carrying and Fair Value of Financial Instrument	The following table summarizes the carrying and fair value of the Company’s financial instruments: December 31, 2018 December 31, 2017 Cash and cash equivalents $ 11,920 $ 7,091 Trade receivables $ 11,292 $ 11,259 Other financial assets $ 11,659 $ 2,491 Other financial liabilities $ 57,198 $ 56,718
Summary of Interest Income and Expense	The following table summarizes interest income and expense for the years ended December 31: 2018 2017 Interest income earned on cash and cash equivalents $ 311 $ — Interest expense from other financial liabilities $ 2,718 $ 2,695
Summary of Net Foreign Exchange Gain or Loss Directing Impacting Net Income (Loss)	At December 31, 2018, the Canadian/U.S. foreign exchange rate was CA$1.00 = US$0.7336 (2017 – US$0.7966). Assuming that all other variables remain constant, an increase of $0.10 in the Canadian dollar would have the following impact on the ending balances of certain consolidated statements of financial position items at December 31, 2018 and December 31, 2017 with the net foreign exchange gain or loss directly impacting net income (loss) for the years. December 31, 2018 December 31, 2017 Financial assets Cash and cash equivalents $ 839 $ 287 Trade receivables 328 349 JV Note receivable 1,335 Financial liabilities Trade payables and accrued liabilities (373 ) (371 ) Loan payable (193 ) (232 ) Net foreign exchange gain (loss) $ 1,936 $ 33
Summary of Contractual Maturities of Financial Liabilities	Liquidity risk is the risk that the Company will not be able to meet its obligations as they fall due. The following are the contractual maturities of financial liabilities as at December 31, 2018: Financial liabilities Total 1 year 2-3 4-5 More than Long-term debt $ 38,588 $ 3,698 $ 34,296 $ 594 $ — Line of credit 2,000 2,000 — — — Trade payables 14,601 14,601 — — — Accrued liabilities 3,509 3,509 — — — Obligation under capital lease 180 78 92 10 — Other liabilities 1,050 — 1,050 — — Total $ 59,928 $ 23,886 $ 35,438 $ 604 $ —

Compensation of Key Management

Compensation of Key Management (Tables)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Summary of Key Management Includes the Company's Officers and Vice Presidents	Key management includes the Company’s officers and vice presidents: Year Ended Year Ended Salaries and other employee benefits $ 2,184 $ 1,778 Share-based payments 629 1,104 $ 2,813 $ 2,882

Expenses by Nature (Tables)

Expenses by Nature (Tables)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Schedule of Significant Expenses by Nature	The following table outlines the Company’s significant expenses by nature: Cost of sales Year Ended Year Ended Purchased produce $ 44,110 $ 41,978 Raw materials and consumables used 32,096 40,365 Depreciation and amortization 6,911 7,447 Transportation and storage 21,074 19,999 Employee compensation and benefits 36,091 34,644 $ 140,282 $ 144,433 Selling, general and administrative expenses Year Ended Year Ended Employee benefits - salaries and short-term benefits $ 8,360 $ 8,422 Employee benefits - share-based payments 1,454 1,519 Marketing 504 617 Professional services 2,120 1,705 Office expenses 1,680 1,671 Other 1,444 1,479 $ 15,562 $ 15,413 Employee compensation and benefits Year Ended Year Ended Salaries and short-term employee benefits $ 44,451 $ 43,066 Share-based compensation 1,454 1,519 $ 45,905 $ 44,585

Income Tax Expense (Tables)

Income Tax Expense (Tables)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Components of Provision for (Recovery of) Income Taxes	The provision for (recovery of) income taxes consists of the following components: Year Ended Year Ended Current $ 431 $ 29 Deferred (2,906 ) 109 Provision for (recovery of) income taxes $ (2,475 ) $ 138
Summary of Principal Differences between Statutory Income Tax (Recovery) and Effective Provision for (Recovery of) Income Taxes	The provision for (recovery of) income taxes reflected in the consolidated statements of (loss) income for the years ended December 31, 2018 and December 31, 2017 differs from the amounts computed at the federal statutory tax rates. The principal differences between the statutory income tax (recovery) and the effective provision for (recovery of) income taxes are summarized as follows: Year Ended Year Ended Income (loss) before income taxes $ (7,620 ) $ 3,960 Tax (recovery) calculated at domestic tax rates applicable in the respective countries (1,595 ) 674 Non-deductible 394 422 True up of prior year income tax estimates (206 ) — Tax rate differences on deferred taxes — (482 ) State tax adjustments — (36 ) Foreign exchange on translation — 132 Unrealized foreign exchange (309 ) 116 Differences attributed to joint venture capital transactions (56 ) (698 ) Share of (income) losses from joint venture (611 ) 66 Other (92 ) (56 ) Provision for (recovery of) income taxes $ (2,475 ) $ 138

Deferred Income Taxes (Tables)

Deferred Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Subclassifications of assets, liabilities and equities [abstract]
Schedule of Deferred Tax Assets and Liabilities	The amounts in the consolidated statements of financial position reconcile to the amounts disclosed in this note as follows: December 31, 2018 December 31, 2017 Deferred tax assets $ 9,599 $ 7,606 Deferred tax liabilities (11,519 ) (12,431 ) $ (1,920 ) $ (4,825 )
Schedule of Change in Deferred Tax Assets and Liabilities	Deferred tax assets: Tax losses/ LT Debt/ Inventory Intangibles Other Total At January 1, 2017 $ 7,413 $ 3,190 $ 518 $ 399 $ 437 $ 11,957 Charged to statement of income (loss) (2,289 ) (968 ) (144 ) (399 ) (551 ) (4,351 ) At December 31, 2017 $ 5,124 $ 2,222 $ 374 $ — $ (114 ) $ 7,606 Credited (charged) to statement of (loss) income 1,053 524 133 — 283 1,993 At December 31, 2018 $ 6,177 $ 2,746 $ 507 $ — $ 169 $ 9,599 Deferred tax liabilities: Accelerated Biological Revaluation Joint Total At January 1, 2017 $ (15,205 ) $ (674 ) $ (1,065 ) $ — $ (16,944 ) Credited (charged) to statement of income (loss) 6,179 214 — (2,151 ) 4,242 Charged to statements of other comprehensive (loss) income — — 271 — 271 At December 31, 2017 $ (9,026 ) $ (460 ) $ (794 ) $ (2,151 ) $ (12,431 ) Credited to statement of (loss) income 567 175 — 170 912 At December 31, 2018 $ (8,459 ) $ (285 ) $ (794 ) $ (1,981 ) $ (11,519 )
Schedule of Analysis of Deferred Tax Assets and Deferred Tax Liabilities	The analysis of deferred tax assets and deferred tax liabilities is as follows: December 31, 2018 December 31, 2017 Canada U.S. Canada U.S. Deferred tax assets: Expected to be recovered in more than 12 months $ 1,155 $ 7,465 $ 747 $ 5,753 Expected to be recovered within 12 months 312 667 388 718 Deferred tax liabilities: Expected to be settled in more than 12 months (4,181 ) (6,251 ) (4,606 ) (6,569 ) Expected to be settled within 12 months (41 ) (1,046 ) (40 ) (1,216 ) Deferred tax liabilities, net of assets $ (2,755 ) $ 835 $ (3,511 ) $ (1,314 )
Schedule of Non-capital and Farm Losses Expire	Non-capital Canada U.S. Total 2021 $ — $ 8,402 $ 8,402 2022 — 5,043 5,043 2023 — 5,117 5,117 2024 — 4,015 4,015 2025 — 8,757 8,757 2027 25 — 25 2028 4 — 4 2029 25 64 89 2030 7 — 7 2031 4 988 992 2032 4 14,895 14,899 2033 4 — 4 2034 4 11,665 11,669 2035 108 7,445 7,553 2036 98 3,583 3,681 2037 98 5,570 5,668 2038 4 9,325 9,329 $ 385 $ 84,869 $ 85,254

Changes in Non-cash Working C_2

Changes in Non-cash Working Capital Items (Tables)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Summary of Change in Non-cash Working Capital Items	For the Years Ended December 31, 2018 2017 Trade receivables $ (46 ) $ (1,059 ) Inventories (5,180 ) (1,197 ) Inventories reclassified to biological asset (659 ) 306 Other receivables 172 (1,396 ) Income taxes payable 68 (246 ) Prepaid expenses and deposits 734 41 Trade payables 1,440 394 Accrued liabilities (121 ) (955 ) Other assets, net of other liabilities 42 (305 ) $ (3,550 ) $ (4,417 )

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Summary of Net Sales by Countries	The Company’s primary operations are in the United States and Canada. Net sales by the countries in which its customers are located are as follows: For the Years Ended December 31, 2018 2017 Sales Produce - U.S. $ 124,699 $ 132,464 Produce - Canada 23,355 24,020 Energy - Canada 1,946 1,922 $ 150,000 $ 158,406
Summary of Property, Plant and Equipment, Net of Accumulated Depreciation by Countries	The Company’s property, plant and equipment, net of accumulated depreciation, are located as follows: December 31, 2018 December 31, 2017 United States $ 43,651 $ 46,922 Canada 30,459 31,183 Energy - Canada 3,369 3,649 $ 77,479 $ 81,754

Share Capital and Equity (Table

Share Capital and Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Summary of Share Capital	The following is a summary of share capital: The VFF Common Shares # of Shares Amount Share capital - January 1, 2017 38,882,945 $ 24,954 Shares issued pursuant to public offering, net 2,500,000 9,769 Shares issued from vesting of RSUs 768,000 1,333 Shares issued on exercise of options 91,667 59 Share capital - December 31, 2017 42,242,612 36,115 Shares issued pursuant to public offering, net 3,097,200 15,737 Shares issued pursuant to private placement, net 1,886,793 7,755 Shares issued from vesting of RSUs 50,334 831 Shares issued on exercise of options 365,732 283 Share capital - December 31, 2018 47,642,671 $ 60,721

Income Per Share (Tables)

Income Per Share (Tables)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Schedule of Weighted Average Number of Common Shares Issued	For the Years Ended December 31, 2018 2017 Net income (loss) attributable to owners of the Company $ (5,145 ) $ 3,822 Weighted average number of common shares outstanding (thousands) 44,357 39,144 Basic income (loss) per share $ ( 0.11 ) $ 0.10
Schedule of Option to Purchase of Common Stock Excluded from Diluted Per Share	For the Years Ended December 31, 2018 2017 Net income (loss) attributable to owners of the Company $ (5,145 ) $ 3,822 Weighted average number of common shares outstanding (thousands) 44,357 39,144 Adjustment for: Share options (thousands) — 1,164 Weighted average number of common shares outstanding for diluted income per share (thousands) 44,357 40,308 Diluted income (loss) per share $ (0.11 ) $ 0.10

Capital Disclosures (Tables)

Capital Disclosures (Tables)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Summary of Capital Comprises Net Debt and Equity	The Company’s capital comprises net debt and equity: December 31, 2018 December 31, 2017 Total bank debt $ 37,859 $ 38,640 Less cash and cash equivalents (11,920 ) (7,091 ) Net debt 25,939 31,549 Total equity 100,696 81,043 $ 126,635 $ 112,592

Share-Based Compensation Plan (

Share-Based Compensation Plan (Tables)	12 Months Ended
	Dec. 31, 2018
Text block [abstract]
Summary of Fair Value Assigned to the Options Issued	The following table presents the assumptions used to establish the fair value assigned to the options issued using the Black-Scholes 2018 2017 Expected volatility 55.5 % 52.7 % Dividend $ nil $ nil Risk-free 2.70 % 2.05 % Expected life 6.5 years 6.5 years Fair value $ 3.2541 $ 3.1869
Summary of Changes in the Stock Options	The changes in the stock options for the years ended December 31, 2018 and 2017 were as follows: For the Years Ended December 31, 2018 2017 Stock options Weighted Stock options Weighted Beginning of year 2,337,732 CA$ 1.59 2,116,065 CA$ 1.19 Granted 203,000 CA$ 5.79 320,000 CA$ 4.04 Exercised (365,733 ) CA$ 0.98 (91,667 ) CA$ 0.90 Forfeitures (10,000 ) CA$ 1.48 (6,666 ) CA$ 1.48 End of year 2,164,999 CA$ 2.10 2,337,732 CA$ 1.59
Summary of Stock Options Outstanding and Granted	The following table summarizes stock options outstanding and granted as at December 31, 2018: Exercise price Number Remaining contractual Number of exercisable CA$1.24 425,000 2.4 425,000 CA$1.27 150,000 3.2 150,000 CA$0.85 100,000 4.2 100,000 CA$1.10 202,000 4.7 202,000 CA$1.48 345,000 5.2 345,000 CA$0.94 100,000 6.2 100,000 CA$0.83 20,000 6.8 20,000 CA$0.80 16,666 6.9 16,666 CA$1.43 233,333 7.3 150,002 CA$1.55 50,000 7.5 33,334 CA$2.20 165,000 8.5 54,999 CA$6.00 155,000 9.0 51,669 CA$5.79 203,000 9.6 Nil 2,164,999
Summary of Share Options Outstanding	Share options outstanding at the end of the year have the following expiry dates and exercise prices: Exercise price in CA$ December 31, December 31, Expiry date - January 13, 2020 0.70 — 149,399 Expiry date - May 20, 2021 1.24 425,000 565,000 Expiry date - March 13, 2022 1.27 150,000 150,000 Expiry date - March 13, 2023 0.85 100,000 100,000 Expiry date - September 26, 2023 1.10 202,000 215,000 Expiry date - March 18, 2024 1.48 345,000 360,000 Expiry date - March 19, 2025 0.94 100,000 100,000 Expiry date - October 6, 2025 0.83 20,000 28,333 Expiry date - November 16, 2025 0.80 16,666 50,000 Expiry date - March 29, 2026 1.43 233,333 250,000 Expiry date - June 30, 2026 1.55 50,000 50,000 Expiry date - June 14, 2027 2.20 165,000 165,000 Expiry date - December 22, 2027 6.00 155,000 155,000 Expiry date - June 5, 2028 5.79 203,000 — 2,164,999 2,337,732
Summary of Performance-Based Restricted Share Units	The following table summarizes 979,000 performance-based restricted share units that were issued during the year. 2018 2017 Performance- Weighted Performance- Weighted Beginning of year 128,000 CA$ 2.82 — Issued 979,000 CA$ 5.79 885,000 CA$ 2.20 Issued — 21,000 CA$ 6.00 Vested (50,334 ) CA$ 3.06 (768,000 ) CA$ 2.20 Expired — (10,000 ) CA$ 2.20 Outstanding at end of year 1,056,666 CA$ 5.56 128,000 CA$ 2.82 Earned but unissued at end of year 175,333 CA$ 5.08 —

Nature of Operations - Addition

Nature of Operations - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2018MW
Nature of operations [line items]
Percentage of equity ownership interest	50.00%
VF Clean Energy Inc [member] | Power plant [member]
Nature of operations [line items]
Generation of Electricity	7

Significant Accounting Polici_4

Significant Accounting Policies, Judgments and Estimation Uncertainty - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2018USD ($)Segment
Disclosure of accounting policies judgments and estimates uncertainty [abstract]
Number of operating segments | Segment	2
Change in financial instruments as a result of changes to measurement categories | $	$ 0
Biological asset measurement beginning period prior to harvest	Six weeks
Period of revaluation of property, plant and equipment	Three years
Stock options, vesting period	Three years
Stock options, vesting rights percentage	33.00%
Stock options, expiration period	10 years
Period of utilizing actual sales price for estimating price of produce on vine	Six weeks

Significant Accounting Polici_5

Significant Accounting Policies, Judgments and Estimation Uncertainty - Summary of Estimated Useful Lives of Property Plant and Equipment (Detail)	12 Months Ended
	Dec. 31, 2018
Bottom of range [member] | Leasehold and land improvements [member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Lives	5 years
Bottom of range [member] | Greenhouses and other buildings [member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Lives	4 years
Bottom of range [member] | Greenhouse equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Lives	3 years
Bottom of range [member] | Machinery and equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Lives	3 years
Maximum [member] | Leasehold and land improvements [member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Lives	20 years
Maximum [member] | Greenhouses and other buildings [member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Lives	30 years
Maximum [member] | Greenhouse equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Lives	30 years
Maximum [member] | Machinery and equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated Useful Lives	12 years

Changes in Accounting Policie_2

Changes in Accounting Policies - Additional Information (Detail) - IFRS 9 financial instruments [member] - USD ($)	Jan. 01, 2018	Dec. 31, 2017
Disclosure of changes in accounting policies [line items]
Financing fees	$ 260
Deferred financing costs		$ 260

Changes in Accounting Policie_3

Changes in Accounting Policies - Summary of Changes in Accounting Policies Adjustments Recognized for Each Individual Line Item (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Jan. 01, 2018	Dec. 31, 2017	Dec. 31, 2016
Non-current liabilities
Long-term debt	$ 32,445	$ 36,020	$ 35,760
Total liabilities	59,119	61,558	61,298
SHAREHOLDERS' EQUITY
Retained earnings	33,867	39,012	39,272
Total shareholders' equity	$ 100,696	$ 80,783	81,043	$ 67,387
Adjustment for adoption of IFRS 9 [member]
Non-current liabilities
Long-term debt			260
Total liabilities			260
SHAREHOLDERS' EQUITY
Retained earnings			(260)
Total shareholders' equity			$ (260)

Inventories - Summary of Invent

Inventories - Summary of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Classes of inventories [line items]
Total Inventories	$ 22,485	$ 17,309
Deferred crop costs [member]
Classes of inventories [line items]
Total Inventories	24,649	19,070
Purchased produce inventory [member]
Classes of inventories [line items]
Total Inventories	643	396
Biological asset adjustment [member]
Classes of inventories [line items]
Total Inventories	(2,871)	(2,212)
Spare parts inventory [member]
Classes of inventories [line items]
Total Inventories	$ 64	$ 55

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Classes of current inventories [abstract]
Cost of inventories recognized as expense	$ 114,236	$ 120,509

Biological Asset - Summary Of B

Biological Asset - Summary Of Biological Asset (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of reconciliation of changes in biological assets [line items]
Biological asset	$ 4,230	$ 4,405
Change in biological asset	(834)	265
Estimated sales value - biological asset [member]
Disclosure of reconciliation of changes in biological assets [line items]
Biological asset	8,004	7,937
Estimated selling costs [member]
Disclosure of reconciliation of changes in biological assets [line items]
Biological asset	470	489
Actual costs [member]
Disclosure of reconciliation of changes in biological assets [line items]
Biological asset	(2,871)	(2,212)
Fair value over cost [member]
Disclosure of reconciliation of changes in biological assets [line items]
Biological asset	1,359	2,193	$ 1,928
Estimated remaining costs to complete [member]
Disclosure of reconciliation of changes in biological assets [line items]
Biological asset	$ 3,304	$ 3,043

Property, Plant and Equipment -

Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about property, plant and equipment [line items]
Property plant and equipment, Beginning Balance	$ 81,754	$ 96,135
Additions/transfers	6,128	1,785
Additions-Capital Lease		191
Placed in service	(3,035)	(93)
Disposals	(630)	(13,045)
Accum deprec on disposal	565	4,122
Depreciation expense	(7,027)	(7,586)
Foreign currency translation adjustment	(276)	245
Property plant and equipment, Ending Balance	77,479	81,754
Property plant and equipment, at cost	156,418	153,666
Property plant and equipment, accumulation depreciation	(78,939)	(71,912)
Land [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property plant and equipment, Beginning Balance	9,112	11,864
Disposals	(65)	(2,752)
Property plant and equipment, Ending Balance	9,047	9,112
Property plant and equipment, at cost	9,047	9,112
Leasehold and land improvements [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property plant and equipment, Beginning Balance	1,597	1,692
Depreciation expense	(85)	(95)
Property plant and equipment, Ending Balance	1,512	1,597
Property plant and equipment, at cost	3,820	3,820
Property plant and equipment, accumulation depreciation	(2,308)	(2,223)
Buildings [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property plant and equipment, Beginning Balance	43,344	50,517
Additions/transfers		(416)
Disposals		(5,524)
Accum deprec on disposal		1,601
Depreciation expense	(2,604)	(2,858)
Foreign currency translation adjustment	(26)	24
Property plant and equipment, Ending Balance	40,714	43,344
Property plant and equipment, at cost	77,003	77,029
Property plant and equipment, accumulation depreciation	(36,289)	(33,685)
Machinery and equipment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property plant and equipment, Beginning Balance	27,233	31,767
Additions/transfers	3,012	789
Additions-Capital Lease		191
Placed in service		1,071
Disposals	(565)	(4,694)
Accum deprec on disposal	565	2,521
Depreciation expense	(4,338)	(4,633)
Foreign currency translation adjustment	(253)	221
Property plant and equipment, Ending Balance	25,654	27,233
Property plant and equipment, at cost	65,996	63,237
Property plant and equipment, accumulation depreciation	(40,342)	(36,004)
Construction in process [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property plant and equipment, Beginning Balance	468	295
Additions/transfers	3,116	1,412
Placed in service	(3,035)	(1,164)
Disposals		(75)
Foreign currency translation adjustment	3
Property plant and equipment, Ending Balance	552	468
Property plant and equipment, at cost	$ 552	$ 468

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Detail) $ in Millions	Dec. 31, 2018USD ($)
Disclosure of detailed information about property, plant and equipment [abstract]
Revaluation surplus related to property, plant and equipment	$ 1.8

Investment in Joint Venture - A

Investment in Joint Venture - Additional Information (Detail) $ in Thousands, $ in Thousands	Jun. 06, 2017CAD ($)	Dec. 31, 2018CAD ($)shares	Dec. 31, 2018USD ($)shares	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2018USD ($)	Jun. 06, 2017USD ($)
Disclosure of joint ventures [line items]
Name of joint venture	Pure Sunfarms Corp.
Investment in joint venture				$ 15,727		$ 18,108
Share of (income) loss from joint venture			$ (2,381)	255
Land and greenhouse facility [member]
Disclosure of joint ventures [line items]
Fair value increas in Delta 3 land					$ 2,100
Amount recorded in accumulated other comprehensive income					$ 1,800
Sunfarms Corp. [member]
Disclosure of joint ventures [line items]
Ownership interest	50.00%
Investment in joint venture				15,727		18,108
Transaction costs related to joint venture		$ 1,400	$ 1,100
Common share purchase warrants related to transaction cost | shares		300,000	300,000
Common share purchase warrants related to transaction cost value		$ 192	$ 148
Share of (income) loss from joint venture		3,084	2,381	$ 255
Sunfarms Corp. [member] | Shareholder [member]
Disclosure of joint ventures [line items]
Shareholders contribution in form of demand loan		$ 13,000				$ 9,959
Interest rate on demand loan		8.00%				8.00%
Sunfarms Corp. [member] | Land and greenhouse facility [member]
Disclosure of joint ventures [line items]
Investment in joint venture	$ 20,000						$ 14,900
Gain (loss) on contribution of assets			$ 8,000

Investment in Joint Venture - S

Investment in Joint Venture - Schedule of Joint Venture Share (Detail) $ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018CAD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Disclosure of joint ventures [line items]
Joint venture beginning balance		$ 15,727
Share of income for the year		(2,381)	$ 255
Joint venture ending balance		18,108	15,727
Sunfarms Corp. [member]
Disclosure of joint ventures [line items]
Joint venture beginning balance		15,727
Share of income for the year	$ 3,084	2,381	255
Joint venture ending balance		$ 18,108	$ 15,727

Investment in Joint Venture -_2

Investment in Joint Venture - Summary Financial Information Joint Venture (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2018	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 11,920	$ 7,091		$ 5,373
Trade receivables	64	70
Inventory	22,485	17,309
Biological asset	4,230	4,405
Current liabilities
Due to joint venture partners	(3,414)	(2,620)
Accumulated deficit	(33,867)	(39,272)	$ (39,012)
Cost of sales	(140,282)	(144,433)
Selling, general and administrative expenses	(15,562)	(15,413)
Change in fair value of bio-asset	(834)	265
Income (loss) from operations	(6,678)	(1,175)
Interest expense, net	(2,407)	(2,695)
Foreign exchange loss	(1,047)	26
(Loss) income before income taxes	(7,620)	3,960
(Provision for) recovery of income taxes	2,475	(138)
Net income (loss)	(5,145)	3,822
Sunfarms Corp. [member]
Current assets
Cash and cash equivalents	2,362	2,907
Trade receivables	1,312
Inventory	8,356	25
Biological asset	7,388
Other current assets	996	210
Current liabilities
Trade payables	(9,361)	(253)
Due to joint venture partners	(26,523)
Other current liabilities	(3,582)	(918)
Non-current liabilities	(2,688)
Net assets	45,523	25,355
Accumulated deficit	5,523	(645)
Contributions from joint venture partners	40,000	26,000
Net assets	45,523	25,355
Revenue	4,917
Cost of sales	(1,542)
Selling, general and administrative expenses	(3,386)	(880)
Change in fair value of bio-asset	8,785
Income (loss) from operations	8,774	(880)
Interest expense, net	(97)
Foreign exchange loss	(234)	(4)
Other income, net	24
(Loss) income before income taxes	8,467	(884)
(Provision for) recovery of income taxes	(2,298)	239
Net income (loss)	$ 6,169	$ (645)

Other Assets - Summary of Other

Other Assets - Summary of Other Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Categories of current financial assets [abstract]
Patronage stock	$ 386	$ 437
Note receivable (note 13)	64	70
Security deposits	540	538
Cash surrender value-insurance	929	924
Other	288	35
Total	$ 2,207	$ 2,004

Debt - Summary of Debt (Detail)

Debt - Summary of Debt (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2018
Long-term debt:
Opening balance	$ 38,640	$ 45,534
IFRS adjustment for deferred financing fees	260
Proceeds from long-term debt		306
Repayment of debt	(2,738)	(7,320)
Foreign currency translation	(43)	120
Closing balance	35,859	38,640
Current portion	3,414	2,620
Non-current portion	32,445	35,760	$ 36,020
Less: Unamortized deferred transaction costs		(260)
Total long-term debt	$ 35,859	$ 38,380

Debt - Additional Information (

Debt - Additional Information (Detail) $ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018CAD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Oct. 31, 2017CAD ($)
Disclosure Of Borrowings [line items]
Outstanding balance amount			$ 35,859	$ 38,380
Outstanding letters of credit	$ 38	$ 261
Accrued interest payable			184	193
Term loan financing agreement with canadian creditor [member]
Disclosure Of Borrowings [line items]
Maturity date	May 1, 2021	May 1, 2021
Outstanding balance amount			34,385
Amortization period of borrowings	15 years	15 years
Term loan financing agreement with canadian creditor [member] | Promissory Notes [member]
Disclosure Of Borrowings [line items]
Carrying value of assets pledged as collateral			$ 114,554	$ 120,815
Term loan financing agreement with canadian creditor [member] | Floating interest rate [member]
Disclosure Of Borrowings [line items]
Interest rate	7.082%		7.082%	5.885%
Loan agreement with Canadian Chartered Bank [member] | Village Farms Clean Energy Inc [member]
Disclosure Of Borrowings [line items]
Maturity date	Maturity date of June 2023	Maturity date of June 2023
Outstanding balance amount			$ 1,279	$ 1,658
Non-revolving fixed rate loan face amount	$ 3,000
Uncommitted, non-revolving credit facility amount	$ 300
Letters of guarantee maximum term	365 days	365 days
Uncommitted credit facility for financing capital expenditures	$ 700
Loan received					$ 250
Uncommitted credit facility repayment period	five-year	five-year
Interest rate basis	Interest rate of CA$ prime rate plus 200 basis points	Interest rate of CA$ prime rate plus 200 basis points
Outstanding balance amount			$ 138	192
Loan agreement with Canadian Chartered Bank [member] | Fixed interest rate [member] | Village Farms Clean Energy Inc [member]
Disclosure Of Borrowings [line items]
Interest rate	4.98%		4.98%
Operating loan with Canadian Chartered Bank [member]
Disclosure Of Borrowings [line items]
Maturity date	Maturity date on May 31, 2021	Maturity date on May 31, 2021
Loan received			$ 2,000	0
Revolving operating loan maximum borrowing amount	$ 13,000
Outstanding letters of credit	$ 38	$ 261
Operating loan with Canadian Chartered Bank [member] | Promissory Notes [member]
Disclosure Of Borrowings [line items]
Carrying value of assets pledged as collateral			$ 38,007	$ 32,883

Debt - Summary of Aggregate Ann

Debt - Summary of Aggregate Annual Maturities of Long-Term Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Borrowings [line items]
Total Long-term debt	$ 35,859	$ 38,380
Later than six months and not later than one year [member]
Disclosure Of Borrowings [line items]
Total Long-term debt	3,414
Later than one year and not later than two years [member]
Disclosure Of Borrowings [line items]
Total Long-term debt	3,409
Later than two years and not later than three years [member]
Disclosure Of Borrowings [line items]
Total Long-term debt	28,551
Later than three years and not later than four years [member]
Disclosure Of Borrowings [line items]
Total Long-term debt	330
Later than four years and not later than five years [member]
Disclosure Of Borrowings [line items]
Total Long-term debt	$ 155

Commitments - Schedule of Futur

Commitments - Schedule of Future Minimum Lease Payment (Detail) $ in Thousands	Dec. 31, 2018USD ($)
Commitments [abstract]
2019	$ 1,253
2020	1,039
2021	1,052
2022	841
2023	618
Thereafter	261
Total	$ 5,064

Commitments - Additional Inform

Commitments - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Commitments [abstract]
Payment of commitment	$ 1,732	$ 1,682

Financial Instruments - Summary

Financial Instruments - Summary of Carrying and Fair Value of Financial Instrument (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about financial instruments [line items]
Cash and cash equivalents	$ 11,920	$ 7,091	$ 5,373
Trade receivables	11,292	11,259
Other financial assets	288	35
Carrying value [member]
Disclosure of detailed information about financial instruments [line items]
Cash and cash equivalents	11,920	7,091
Trade receivables	11,292	11,259
Other financial assets	11,659	2,491
Other financial liabilities	57,198	56,718
Fair value [member]
Disclosure of detailed information about financial instruments [line items]
Cash and cash equivalents	11,920	7,091
Trade receivables	11,292	11,259
Other financial assets	11,659	2,491
Other financial liabilities	$ 57,198	$ 56,718

Financial Instruments- Addition

Financial Instruments- Additional Information (Detail)	12 Months Ended
	Dec. 31, 2018CAD ($)Customers	Dec. 31, 2018USD ($)Customers	Dec. 31, 2017USD ($)Customers
Disclosure of detailed information about financial instruments [line items]
Transfers of assets or liabilities between levels		$ 0	$ 0
Outstanding letters of credit	$ 38,000	$ 261,000
Interest rate risk [member]
Disclosure of detailed information about financial instruments [line items]
Higher in risk assumption	0.50%	0.50%
Loss for the year would have been higher in risk assumption		$ 182,000	$ 201,000
LIBOR measurement period	90 days	90 days
Currency risk [member]
Disclosure of detailed information about financial instruments [line items]
Foreign currency exchange rate for canadian dollar	1	1
Foreign currency exchange rate for us dollar	0.7336	0.7336	0.7966
Increase decrease in foreign currency exchange rate	$ 0.10
Less than 30 days [member]
Disclosure of detailed information about financial instruments [line items]
Percentage of trade receivables outstanding balance	90.30%	90.30%	89.40%
Between 30 and 90 days [member]
Disclosure of detailed information about financial instruments [line items]
Percentage of trade receivables outstanding balance	8.30%	8.30%	7.40%
More than 90 days [member]
Disclosure of detailed information about financial instruments [line items]
Percentage of trade receivables outstanding balance	1.40%	1.40%	3.20%
Maximum [member]
Disclosure of detailed information about financial instruments [line items]
Operating credit facility	$ 13,000,000
Customer one [member]
Disclosure of detailed information about financial instruments [line items]
Percentage of balance of trade receivables	13.80%	13.80%	16.00%
Customer two [member]
Disclosure of detailed information about financial instruments [line items]
Percentage of balance of trade receivables	11.50%	11.50%	14.80%
Trade receivables [member]
Disclosure of detailed information about financial instruments [line items]
Number of customers with benchmark contribution of more than 10% | Customers	2	2	2

Financial Instruments - Summa_2

Financial Instruments - Summary of Interest Income and Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about financial instruments [abstract]
Interest income earned on cash and cash equivalents	$ 311
Interest expense from other financial liabilities	$ 2,718	$ 2,695

Financial Instruments - Summa_3

Financial Instruments - Summary of Net Foreign Exchange Gain or Loss Directing Impacting Net Income (Loss) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about financial commitments [line items]
Net foreign exchange gain (loss)	$ (1,047)	$ 26
Cash and cash equivalents [member]
Disclosure of detailed information about financial commitments [line items]
Net foreign exchange gain (loss)	839	287
Trade receivables [member]
Disclosure of detailed information about financial commitments [line items]
Net foreign exchange gain (loss)	328	349
Joint venture note receivable [member]
Disclosure of detailed information about financial commitments [line items]
Net foreign exchange gain (loss)	1,335
Trade payables and accrued liabilities [member]
Disclosure of detailed information about financial commitments [line items]
Net foreign exchange gain (loss)	(373)	(371)
Loan payable [member]
Disclosure of detailed information about financial commitments [line items]
Net foreign exchange gain (loss)	$ (193)	$ (232)

Financial Instruments - Summa_4

Financial Instruments - Summary of Contractual Maturities of Financial Liabilities (Detail) $ in Thousands	Dec. 31, 2018USD ($)
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	$ 59,928
Not later than one year [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	23,886
Later than two years and not later than three years [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	35,438
Later than four years and not later than five years [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	604
Long-term debt [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	38,588
Long-term debt [member] | Not later than one year [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	3,698
Long-term debt [member] | Later than two years and not later than three years [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	34,296
Long-term debt [member] | Later than four years and not later than five years [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	594
Line of credit [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	2,000
Line of credit [member] | Not later than one year [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	2,000
Trade payables [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	14,601
Trade payables [member] | Not later than one year [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	14,601
Accrued liabilities [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	3,509
Accrued liabilities [member] | Not later than one year [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	3,509
Obligation under capital lease [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	180
Obligation under capital lease [member] | Not later than one year [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	78
Obligation under capital lease [member] | Later than two years and not later than three years [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	92
Obligation under capital lease [member] | Later than four years and not later than five years [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	10
Other liabilities [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	1,050
Other liabilities [member] | Later than two years and not later than three years [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Financial liabilities	$ 1,050

Related Party Transactions an_2

Related Party Transactions and Balances - Additional Information (Detail) $ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2018CAD ($)	Dec. 31, 2018USD ($)
Disclosure of related party transactions [line items]
Executive management salaries for services	$ 108	$ 98
Sunfarms Corp. [member]
Disclosure of related party transactions [line items]
Due from joint ventures		411		$ 1,079
Loan agreement entered date with share holders	Jul. 5, 2018
Shareholder [member] | Sunfarms Corp. [member]
Disclosure of related party transactions [line items]
Due to related parties			$ 13,000	$ 9,959
Interest rate percentage on due to related parties			8.00%	8.00%
Employee [member] | Other assets [member]
Disclosure of related party transactions [line items]
Promissory note due from related party		$ 70		$ 64

Compensation of Key Managemen_2

Compensation of Key Management - Summary of Key Management Includes the Company's Officers and Vice Presidents (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of transactions between related parties [abstract]
Salaries and other employee benefits	$ 2,184	$ 1,778
Share-based payments	629	1,104
Key management personnel compensation	$ 2,813	$ 2,882

Expenses by Nature - Schedule o

Expenses by Nature - Schedule of Significant Expenses by Nature (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of transactions between related parties [abstract]
Purchased produce	$ 44,110	$ 41,978
Raw materials and consumables used	32,096	40,365
Depreciation and amortization	6,911	7,447
Transportation and storage	21,074	19,999
Employee compensation and benefits	36,091	34,644
Cost of sales	140,282	144,433
Employee benefits - salaries and short-term benefits	8,360	8,422
Employee benefits - share-based payments	1,454	1,519
Marketing	504	617
Professional services	2,120	1,705
Office expenses	1,680	1,671
Other	1,444	1,479
Selling, general and administrative expenses	15,562	15,413
Salaries and short-term employee benefits	44,451	43,066
Share-based compensation	1,454	1,519
Employee compensation and benefits	$ 45,905	$ 44,585

Income Tax Expense - Components

Income Tax Expense - Components of Provision for (Recovery of) Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Major components of tax expense (income) [abstract]
Current	$ 431	$ 29
Deferred	(2,906)	109
Provision for (recovery of) income taxes	$ (2,475)	$ 138

Income Tax Expense - Summary of

Income Tax Expense - Summary of Principal Differences between Statutory Income Tax (Recovery) and Effective Provision for (Recovery of) Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of accounting profit multiplied by applicable tax rates [abstract]
Income (loss) before income taxes	$ (7,620)	$ 3,960
Tax (recovery) calculated at domestic tax rates applicable in the respective countries	(1,595)	674
Non-deductible items	394	422
True up of prior year income tax estimates	(206)
Tax rate differences on deferred taxes		(482)
State tax adjustments		(36)
Foreign exchange on translation		132
Unrealized foreign exchange	(309)	116
Differences attributed to joint venture capital transactions	(56)	(698)
Share of (income) losses from joint venture	(611)	66
Other	(92)	(56)
Provision for (recovery of) income taxes	$ (2,475)	$ 138

Income Tax Expense - Additional

Income Tax Expense - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of income tax [line items]
Weighted average applicable tax rate	32.30%	3.50%
Canada [member]
Disclosure of income tax [line items]
Statutory tax rate in effect	27.00%	26.00%
United States [member]
Disclosure of income tax [line items]
Statutory tax rate in effect	21.00%	23.00%

Deferred income Taxes - Schedul

Deferred income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Deferred income taxes [abstract]
Deferred tax assets	$ 9,599	$ 7,606	$ 11,957
Deferred tax liabilities	(11,519)	(12,431)	$ (16,944)
Deferred tax liabilities, net of assets	$ (1,920)	$ (4,825)

Deferred Income Taxes - Sched_2

Deferred Income Taxes - Schedule of Change in Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets
Deferred tax assets beginning balance	$ 7,606	$ 11,957
Credited (charged) to statement of (loss) income	1,993	(4,351)
Deferred tax assets Ending balance	9,599	7,606
Deferred tax liabilities:
Deferred tax liabilities beginning balance	(12,431)	(16,944)
Credited (charged) to statement of income (loss)	912	4,242
Charged to statements of other comprehensive (loss) income		271
Deferred tax liabilities Ending balance	(11,519)	(12,431)
Tax losses/other credits [member]
Deferred tax assets
Deferred tax assets beginning balance	5,124	7,413
Credited (charged) to statement of (loss) income	1,053	(2,289)
Deferred tax assets Ending balance	6,177	5,124
LT Debt/Interest [member]
Deferred tax assets
Deferred tax assets beginning balance	2,222	3,190
Credited (charged) to statement of (loss) income	524	(968)
Deferred tax assets Ending balance	2,746	2,222
Inventory [member]
Deferred tax assets
Deferred tax assets beginning balance	374	518
Credited (charged) to statement of (loss) income	133	(144)
Deferred tax assets Ending balance	507	374
Intangibles [member]
Deferred tax assets
Deferred tax assets beginning balance		399
Credited (charged) to statement of (loss) income		(399)
Other [member]
Deferred tax assets
Deferred tax assets beginning balance	(114)	437
Credited (charged) to statement of (loss) income	283	(551)
Deferred tax assets Ending balance	169	(114)
Accelerated tax depreciation [member]
Deferred tax liabilities:
Deferred tax liabilities beginning balance	(9,026)	(15,205)
Credited (charged) to statement of income (loss)	567	6,179
Deferred tax liabilities Ending balance	(8,459)	(9,026)
Biological asset [member]
Deferred tax liabilities:
Deferred tax liabilities beginning balance	(460)	(674)
Credited (charged) to statement of income (loss)	175	214
Deferred tax liabilities Ending balance	(285)	(460)
Revaluation surplus [member]
Deferred tax liabilities:
Deferred tax liabilities beginning balance	(794)	(1,065)
Charged to statements of other comprehensive (loss) income		271
Deferred tax liabilities Ending balance	(794)	(794)
Joint venture shares [member]
Deferred tax liabilities:
Deferred tax liabilities beginning balance	(2,151)
Credited (charged) to statement of income (loss)	170	(2,151)
Deferred tax liabilities Ending balance	$ (1,981)	$ (2,151)

Deferred income Taxes - Sched_3

Deferred income Taxes - Schedule of Analysis of Deferred Tax Assets and Deferred Tax Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax liabilities:
Expected to be settled in more than 12 months	$ (1,920)	$ (4,825)
Deferred tax liabilities, net of assets	(1,920)	(4,825)
Canada [member]
Deferred tax assets:
Expected to be recovered in more than 12 months	1,155	747
Expected to be recovered within 12 months	312	388
Deferred tax liabilities:
Expected to be settled in more than 12 months	(4,181)	(4,606)
Expected to be settled within 12 months	(41)	(40)
Deferred tax liabilities, net of assets	(2,755)	(3,511)
United States [member]
Deferred tax assets:
Expected to be recovered in more than 12 months	7,465	5,753
Expected to be recovered within 12 months	667	718
Deferred tax liabilities:
Expected to be settled in more than 12 months	(6,251)	(6,569)
Expected to be settled within 12 months	(1,046)	(1,216)
Deferred tax liabilities, net of assets	$ 835	$ (1,314)

Deferred income Taxes - Sched_4

Deferred income Taxes - Schedule of Non-capital and Farm Losses Expire (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	$ 85,254
Canada [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	385
United States [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	84,869
2021 [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	8,402
2021 [member] | United States [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	8,402
2022 [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	5,043
2022 [member] | United States [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	5,043
2023 [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	5,117
2023 [member] | United States [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	5,117
2024 [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	4,015
2024 [member] | United States [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	4,015
2025 [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	8,757
2025 [member] | United States [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	8,757
2027 [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	25
2027 [member] | Canada [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	25
2028 [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	4
2028 [member] | Canada [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	4
2029 [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	89
2029 [member] | Canada [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	25
2029 [member] | United States [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	64
2030 [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	7
2030 [member] | Canada [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	7
2031 [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	992
2031 [member] | Canada [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	4
2031 [member] | United States [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	988
2032 [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	14,899
2032 [member] | Canada [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	4
2032 [member] | United States [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	14,895
2033 [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	4
2033 [member] | Canada [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	4
2034 [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	11,669
2034 [member] | Canada [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	4
2034 [member] | United States [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	11,665
2035 [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	7,553
2035 [member] | Canada [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	108
2035 [member] | United States [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	7,445
2036 [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	3,681
2036 [member] | Canada [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	98
2036 [member] | United States [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	3,583
2037 [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	5,668
2037 [member] | Canada [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	98
2037 [member] | United States [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	5,570
2038 [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	9,329
2038 [member] | Canada [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	4
2038 [member] | United States [member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused Non Capital And Farm Losses	$ 9,325

Changes in Non-cash Working C_3

Changes in Non-cash Working Capital Items - Summary of Change in Non-cash Working Capital Items (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Cash Flow Statement [abstract]
Trade receivables	$ (46)	$ (1,059)
Inventories	(5,180)	(1,197)
Inventories reclassified to biological asset	(659)	306
Other receivables	172	(1,396)
Income taxes payable	68	(246)
Prepaid expenses and deposits	734	41
Trade payables	1,440	394
Accrued liabilities	(121)	(955)
Other assets, net of other liabilities	42	(305)
Changes in non-cash working capital items	$ (3,550)	$ (4,417)

Segment and Geographic Inform_3

Segment and Geographic Information - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)Segments	Dec. 31, 2017USD ($)
Disclosure of operating segments [line items]
Number of reporting segments | Segments	2
Depreciation and amortization charges	$ 6,911	$ 7,447
Produce [member]
Disclosure of operating segments [line items]
Depreciation and amortization charges	6,154	6,791
Energy [member]
Disclosure of operating segments [line items]
Depreciation and amortization charges	$ 873	$ 795

Segment and Geographic Inform_4

Segment and Geographic Information - Summary of Net Sales by Countries (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of operating segments [line items]
Sales	$ 150,000	$ 158,406
United States [member] | Produce [member]
Disclosure of operating segments [line items]
Sales	124,699	132,464
Canada [member] | Produce [member]
Disclosure of operating segments [line items]
Sales	23,355	24,020
Canada [member] | Energy [member]
Disclosure of operating segments [line items]
Sales	$ 1,946	$ 1,922

Segment and Geographic Inform_5

Segment and Geographic Information - Summary of Property, Plant and Equipment, Net of Accumulated Depreciation by Countries (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of geographical areas [line items]
Property, plant and equipment, net of accumulated depreciation	$ 77,479	$ 81,754	$ 96,135
United States [member]
Disclosure of geographical areas [line items]
Property, plant and equipment, net of accumulated depreciation	43,651	46,922
Canada [member]
Disclosure of geographical areas [line items]
Property, plant and equipment, net of accumulated depreciation	30,459	31,183
Canada [member] | Energy [member]
Disclosure of geographical areas [line items]
Property, plant and equipment, net of accumulated depreciation	$ 3,369	$ 3,649

Share Capital and Equity - Summ

Share Capital and Equity - Summary of Share Capital (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of classes of share capital [abstract]
Beginning balance, shares	42,242,612	38,882,945
Shares issued pursuant to public offering, net	3,097,200	2,500,000
Shares issued pursuant to private placement, net	1,886,793
Shares issued from vesting of RSUs	50,334	768,000
Shares issued on exercise of options	365,732	91,667
Ending balance, Shares	47,642,671	42,242,612
Beginning balance	$ 81,043	$ 67,387
Shares issued pursuant to public offering, net	15,737	9,769
Shares issued pursuant to private placement, net	7,755
Shares issued from vesting of RSUs	831	1,333
Shares issued on exercise of options	283	59
Ending balance	$ 100,696	$ 81,043

Income Per Share - Schedule of

Income Per Share - Schedule of Weighted Average Number of Common Shares Issued (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Earnings per share [abstract]
Net income (loss) attributable to owners of the Company	$ (5,145)	$ 3,822
Weighted average number of common shares outstanding (thousands)	44,357	39,144
Basic income (loss) per share	$ (0.11)	$ 0.10

Income Per Share - Additional I

Income Per Share - Additional Information (Detail) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Earnings per share [abstract]
Number of options to purchase common stock excluded from diluted loss per share computation	2,175	0

Income Per Share - Schedule o_2

Income Per Share - Schedule of Option to Purchase of Common Stock Excluded from Diluted Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Earnings per share [abstract]
Net income (loss) attributable to owners of the Company	$ (5,145)	$ 3,822
Weighted average number of common shares outstanding (thousands)	44,357	39,144
Share options (thousands)		$ 1,164
Adjustments to net income per share		$ 61
Weighted average number of common shares outstanding for diluted income per share (thousands)	44,357	40,308
Diluted income (loss) per share	$ (0.11)	$ 0.10

Disclosure - Capital Disclosure

Disclosure - Capital Disclosures - Summary of Capital Comprises Net Debt and Equity (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Jan. 01, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of net debt and equity [abstract]
Total bank debt	$ 37,859		$ 38,640
Less cash and cash equivalents	(11,920)		(7,091)	$ (5,373)
Net debt	25,939		31,549
Total equity	100,696	$ 80,783	81,043	$ 67,387
Net debt and equity	$ 126,635		$ 112,592

Capital Disclosures - Additiona

Capital Disclosures - Additional Information (Detail) $ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018CAD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Disclosure of capital disclosure [line items]
Outstanding letters of credit	$ 38	$ 261
Operating loan outstanding amount		$ 2,000	$ 0
Operating loan borrowing base amount	11,509
Maximum [member]
Disclosure of capital disclosure [line items]
Operating loan facility amount	$ 13,000

Share-Based Compensation Plan -

Share-Based Compensation Plan - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Maximum number of common shares that can be issued upon exercise of options granted equal to percentage of number of common shares issued and outstanding	10.00%
Term during which an option may be exercised	10 years
Options vest at a rate	33.00%
Description of vesting requirements for share based payment arrangement	Options vest at a rate of 33% per year, beginning one year following the grant date of the options.
Share-based compensation expense	$ 1,454	$ 1,519
Performance based restricted stock units [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments other equity instruments granted		21,000
Number of other equity instruments outstanding in share based payment arrangement	1,056,666	128,000
Number of non-vested other equity instruments outstanding in share based payment arrangement	881,333
Performance based restricted stock units [member] | Exercise price in CA$ 5.79 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of instruments other equity instruments granted	979,000	885,000

Share-Based Compensation Plan_2

Share-Based Compensation Plan - Summary of Fair Value Assigned to the Options Issued (Detail)	12 Months Ended
	Dec. 31, 2018USD ($)yr	Dec. 31, 2017USD ($)yr
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Expected volatility	55.50%	52.70%
Dividend	0.00%	0.00%
Risk-free interest rate	2.70%	2.05%
Expected life | yr	6.5	6.5
Fair value | $	$ 3.2541	$ 3.1869

Share-Based Compensation Plan_3

Share-Based Compensation Plan - Summary of Changes in the Stock Options (Detail)	12 Months Ended
	Dec. 31, 2018CAD ($)	Dec. 31, 2017CAD ($)
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Beginning of year	2,337,732	2,116,065
Granted	203,000	320,000
Exercised	(365,733)	(91,667)
Forfeitures	(10,000)	(6,666)
End of year	2,164,999	2,337,732
Beginning of year	$ 1.59	$ 1.19
Granted	5.79	4.04
Exercised	0.98	0.90
Forfeitures	1.48	1.48
End of year	$ 2.10	$ 1.59

Share-Based Compensation Plan_4

Share-Based Compensation Plan - Summary of Stock Options Outstanding and Granted (Detail)	Dec. 31, 2018CAD ($)yr	Dec. 31, 2017	Dec. 31, 2016
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	2,164,999	2,337,732	2,116,065
Stock option 1 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	2,164,999	2,337,732
Stock option 1 [member] | Exercise price in CA$ 1.24 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	425,000	565,000
Remaining contractual life (years) | yr	2.4
Number of exercisable options	425,000
Exercise price | $	$ 1.24
Stock option 1 [member] | Exercise price in CA$ 1.27 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	150,000	150,000
Remaining contractual life (years) | yr	3.2
Number of exercisable options	150,000
Exercise price | $	$ 1.27
Stock option 1 [member] | Exercise price in CA$ 0.85 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	100,000	100,000
Remaining contractual life (years) | yr	4.2
Number of exercisable options	100,000
Exercise price | $	$ 0.85
Stock option 1 [member] | Exercise price in CA$ 1.1 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	202,000	215,000
Remaining contractual life (years) | yr	4.7
Number of exercisable options	202,000
Exercise price | $	$ 1.10
Stock option 1 [member] | Exercise price in CA$ 1.48 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	345,000	360,000
Remaining contractual life (years) | yr	5.2
Number of exercisable options	345,000
Exercise price | $	$ 1.48
Stock option 1 [member] | Exercise price in CA$ 0.94 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	100,000	100,000
Remaining contractual life (years) | yr	6.2
Number of exercisable options	100,000
Exercise price | $	$ 0.94
Stock option 1 [member] | Exercise price in CA$ 0.83 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	20,000	28,333
Remaining contractual life (years) | yr	6.8
Number of exercisable options	20,000
Exercise price | $	$ 0.83
Stock option 1 [member] | Exercise price in CA$ 0.8 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	16,666	50,000
Remaining contractual life (years) | yr	6.9
Number of exercisable options	16,666
Exercise price | $	$ 0.80
Stock option 1 [member] | Exercise price in CA$ 1.43 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	233,333	250,000
Remaining contractual life (years) | yr	7.3
Number of exercisable options	150,002
Exercise price | $	$ 1.43
Stock option 1 [member] | Exercise price in CA$ 1.55 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	50,000	50,000
Remaining contractual life (years) | yr	7.5
Number of exercisable options	33,334
Exercise price | $	$ 1.55
Stock option 1 [member] | Exercise price in CA$ 2.2 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	165,000	165,000
Remaining contractual life (years) | yr	8.5
Number of exercisable options	54,999
Exercise price | $	$ 2.20
Stock option 1 [member] | Exercise price in CA$ 6 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	155,000	155,000
Remaining contractual life (years) | yr	9
Number of exercisable options	51,669
Exercise price | $	$ 6
Stock option 1 [member] | Exercise price in CA$ 5.79 [member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding	203,000
Remaining contractual life (years) | yr	9.6
Number of exercisable options
Exercise price | $	$ 5.79

Share-Based Compensation Plan_5

Share-Based Compensation Plan - Summary of Share Options Outstanding (Detail)	12 Months Ended
	Dec. 31, 2018CAD ($)	Dec. 31, 2017	Dec. 31, 2016
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	2,164,999	2,337,732	2,116,065
Stock option 1 [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	2,164,999	2,337,732
Stock option 1 [member] | Exercise price in CA$ 0.7 [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	$ 0.70
Exercise price		149,399
Expiry date	Expiry date - January 13, 2020
Stock option 1 [member] | Exercise price in CA$ 1.24 [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	$ 1.24
Exercise price	425,000	565,000
Expiry date	Expiry date - May 20, 2021
Stock option 1 [member] | Exercise price in CA$ 1.27 [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	$ 1.27
Exercise price	150,000	150,000
Expiry date	Expiry date - March 13, 2022
Stock option 1 [member] | Exercise price in CA$ 0.85 [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	$ 0.85
Exercise price	100,000	100,000
Expiry date	Expiry date - March 13, 2023
Stock option 1 [member] | Exercise price in CA$ 1.1 [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	$ 1.10
Exercise price	202,000	215,000
Expiry date	Expiry date - September 26, 2023
Stock option 1 [member] | Exercise price in CA$ 1.48 [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	$ 1.48
Exercise price	345,000	360,000
Expiry date	Expiry date - March 18, 2024
Stock option 1 [member] | Exercise price in CA$ 0.94 [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	$ 0.94
Exercise price	100,000	100,000
Expiry date	Expiry date - March 19, 2025
Stock option 1 [member] | Exercise price in CA$ 0.83 [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	$ 0.83
Exercise price	20,000	28,333
Expiry date	Expiry date - October 6, 2025
Stock option 1 [member] | Exercise price in CA$ 0.8 [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	$ 0.80
Exercise price	16,666	50,000
Expiry date	Expiry date - November 16, 2025
Stock option 1 [member] | Exercise price in CA$ 1.43 [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	$ 1.43
Exercise price	233,333	250,000
Expiry date	Expiry date - March 29, 2026
Stock option 1 [member] | Exercise price in CA$ 1.55 [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	$ 1.55
Exercise price	50,000	50,000
Expiry date	Expiry date - June 30, 2026
Stock option 1 [member] | Exercise price in CA$ 2.2 [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	$ 2.20
Exercise price	165,000	165,000
Expiry date	Expiry date - June 14, 2027
Stock option 1 [member] | Exercise price in CA$ 6 [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	$ 6
Exercise price	155,000	155,000
Expiry date	Expiry date - December 22, 2027
Stock option 1 [member] | Exercise price in CA$ 5.79 [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	$ 5.79
Exercise price	203,000
Expiry date	Expiry date - June 5, 2028

Share-Based Compensation Plan_6

Share-Based Compensation Plan - Summary of Performance-Based Restricted Share Units (Detail) - Performance based restricted stock units [member]	12 Months Ended
	Dec. 31, 2018CAD ($)	Dec. 31, 2017CAD ($)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Beginning of year	$ 2.82
Issued		$ 6
Vested	3.06	2.20
Expired		2.20
Outstanding at end of year	5.56	$ 2.82
Earned but unissued at end of year	$ 5.08
Beginning of year	128,000
Issued		21,000
Vested	(50,334)	(768,000)
Expired		(10,000)
Outstanding at end of year	1,056,666	128,000
Earned but unissued at end of year	175,333
Exercise price in CA$ 5.79 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Issued	$ 5.79	$ 2.20
Issued	979,000	885,000

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - USD ($) $ in Millions	Mar. 01, 2019	Dec. 31, 2018
Disclosure of non-adjusting events after reporting period [line items]
Initial trading date		Feb. 21, 2019
Village Fields Hemp [member] | Events after reporting period [member]
Disclosure of non-adjusting events after reporting period [line items]
Proportion of ownership interest in joint venture	65.00%
Start-up costs and working capital	$ 15
Nature Crisp LLC [member] | Events after reporting period [member]
Disclosure of non-adjusting events after reporting period [line items]
Proportion of ownership interest in joint venture	35.00%